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A Symposium on Nutrition and Cognition: Towards Research and Application for Different Life Stages was held 
on October 2010 in Malaysia. The influence of diet and nutrition on the cognitive development of the child and 
on cognitive decline in later life was reviewed. Central to the study of such topics is the assessment of cognitive 
functioning. Cognitive functioning falls into six main areas: executive functioning, memory, attention, perception, 
psychomotor and language skills, although each domain can be further subdivided. As it is in the nature of human 
functioning that the performance on any cognitive test can reflect aspects of many of these domains, ideally a bat-
tery of tests should be used to establish the basis of any difference in performance. In intervention studies, fre-
quently there has been a failure to demonstrate a beneficial influence of changes in diet. A possible reason is that 
studies have failed to acknowledge the time scale and critical ages over which diet has an impact. Diet may have 
a slow and progressive influence making it difficult for short-term studies to show an improvement. In addition, 
as many factors influence human behaviour, dietary interventions should only be one part of a coordinated ap-
proach; the effect of diet will depend on the social and psychological context in which an individual lives. Placing 
diet into a broader social and psychological context greatly increases the chance of generating significant findings. 
This report highlights and reviews presentations and discussions at the symposium. 
 





Southeast Asia still faces problems of inadequate nutri-
tion in sections of the population; and to date most atten-
tion has been directed to preventing deficiency diseases, 
with an emphasis on the provision of adequate energy and 
protein, as well as specific nutrients such as iodine, iron 
and vitamin A. Both a deficiency of iodine and iron, 
when the brain is initially developing, results in irreversi-
ble damage. Vitamin A deficiency is the leading cause of 
preventable blindness in children; and in pregnant women, 
increases the risk of maternal mortality. However, in 
those sections of the population where clinical deficiency 
is no longer a problem, there arises an interest in ensuring 
that nutrition is sufficient to allow optimal cognitive de-
velopment and to slow cognitive decline in later years. 
Therefore a symposium took place, entitled Nutrition and 
Cognition: Towards Research and Application for Differ-
ent Life Stages, on October 19-21, 2010, in Kuala Lum-
pur Malaysia, to: 1) share the state-of-the-art knowledge 
on the relationship between nutrition and cognition; 2) 
highlight current methodologies in assessing cognitive 
functions, and explore their applicability for different 
population groups and life stages; 3) discuss issues relat-
ing to scientific substantiation of cognition related claims; 
and 4) consider consumer understanding of nutritional 
influences on cognition. The meeting was organized by 
the International Life Sciences Institute Southeast Asia 
Region, the Nutrition Society of Malaysia in collabora-
tion with the Australian based Commonwealth Scientific 
and Industrial Research Organization.  
    The present report summarizes a wide-ranging and 
lively meeting during which there were a number of 
broad themes: 1) role of nutrition in cognitive develop-
ment; 2) role of nutrition in cognitive performance and 
degeneration; 3) assessment of cognitive functions; and 4) 
evidence-based claims and consumer understanding on 
cognition. The choice of cognitive measures is crucial and 
must be relevant for the target population. There is no 
“one size fits all” cognitive battery that can be used in 
nutrition intervention studies, rather assessment tools 
need to be tailored to the target groups and research needs. 
 
Corresponding Author: Dr David Benton, Department of Psy-
chology, University of Swansea, Swansea, Wales SA2 8PP, 
United Kingdom.  
Tel: +44 (0) 1792 295607; Fax: +44 (0) 1792 295679  
Email: d.benton@swansea.ac.uk 
Manuscript received 15 July 2011. Accepted 15 August 2011. 
 Symposium on nutrition and cognition   105 
 
The impact of nutrition on cognition is likely to begin 
very early; nutrition in the pre-natal stage can be influen-
tial throughout the lifespan. Thus early nutrition was con-
sidered, but also nutrition in later life, as in South-East 
Asia the population is ageing rapidly with an expectation 
that the incidence of dementia will increase. How targeted 
nutrition can assist in both development and aging is be-
ing actively explored. There is potentially a characteristic 
Asian contribution to this area, given the history of using 
spices and herbs as traditional medicines, there is a poten-
tial to provide novel foods. 
    Asian cultures tend to take pride in their child being 
‘smart’ but also favour a long and healthy life. Such fac-
tors generate a strong interest in the influence of nutrition 
on cognitive functioning at all life stages. It follows that 
consumer understanding of any nutritionally based claim, 
the form of the wording on the packet, is important. Not 
only does a claim need to be scientifically defensible but 
the words used need to communicate the intended mean-
ing to the general public that is not likely to understand 
scientific jargon, while the small differences in meaning 
that are important to specialists are reasonably retained. 
In turn regulators require appropriate and substantial evi-
dence for claims in the area of nutrition and cognition that 
are specific, quantifiable and relate to specific target 
groups. 
    The organization of this report reflects the topics con-
sidered during the meeting. 
 
NUTRITION AND COGNITIVE DEVELOPMENT 
DURING GROWTH AND DEVELOPMENT  
Protein-energy malnutrition adversely affects early devel-
opment by changing structural proteins and the produc-
tion of neurotransmitters.1 Nutritional deficiency is com-
mon among women, infants and young children through-
out the developing world. Whereas cost-effective inter-
ventions to alleviate these problems have been identified, 
global efforts continue to be necessary to harmonize these 
efforts by working with affected populations to improve 
the environment and hence human capacity.2  The influ-
ence of several micronutrients on cognition has been ex-
plicitly identified as having a role in achieving the Mil-
lennium Development Goals (MDG). Micronutrient sup-
plementation has a significant role in facilitating human 
development in the context of reducing the effects of 
poverty (MDG1) and enhancing primary education 
(MDG2), as well as promoting gender equity (MDG3). 
Moreover, an adequate micronutrient status helps to re-
duce common childhood infections, maternal morbidity 
and the outcome of pregnancy, leading to a reduction of 
child mortality (MDG4) and improved maternal health 
(MDG5).3  
 
Prevalence of malnutrition worldwide  
Globally, 13 million children are born annually with in-
trauterine growth restriction; 112 million are underweight, 
55 million children are wasted, 19 million suffer from 
chronic and acute malnutrition. One hundred and seventy 
eight million children under five were stunted, mostly in 
south Asia and sub-Saharan Africa.4 Maternal short stat-
ure (height <145 cm) was most prevalent in south Asia, 
and 10-19% of women aged 15–49 years had low body-
mass index. Stunting, severe wasting, and intrauterine 
growth restriction together were responsible for about two 
million deaths and 21% of disability-adjusted life-years 
(DALYs) for children under five. In Asia, 31.3% and 
22% of children under five were stunted (short stature) 
and underweight, respectively, and 3.7% were severely 
wasted (thin). South-central Asia had the highest preva-
lence of all of these undernourished conditions (stunting: 
40.7%, 73.8 million; severe wasting: 5.7%, 10.3 million; 
underweight: 33.1%, 60.1 million), followed by Southeast 
Asia where 12.4% of term babies were born with a low 
birth weight (<2500 g), that reflected poor maternal nutri-
tion and retardation of intrauterine growth. South-central 
Asia also has a high prevalence; 19.9% or approximately 
8 million of live births are of a low weight. Inadequate 
breastfeeding was responsible for 1.4 million child deaths 
and 44 million or 10% of DALYs amongst those under 
five.5  
    Iron deficiency anaemia resulted in about one-fifth of 
maternal deaths and accounted for 0.4% of global total 
DALYs. In turn, vitamin A and zinc deficiencies were 
responsible for one million deaths and a combined 9% of 
global childhood DALYs. In addition iron and iodine 
deficiencies combined, were responsible for about 0.2% 
of global childhood DALYs.5 National prevalence data on 
micronutrient deficiencies are, however, very limited. 
Based on the WHO data base, five millions children had 
night blindness associated with vitamin A deficiency.3 It 
was also estimated that the deaths of 20-24% of children 
who died of measles, diarrhoea and malaria were attribut-
able to vitamin A and zinc deficiencies. Each year, 38 
million newborns are at risk of iodine deficiency. Glob-
ally, 47% of those under five suffered from anaemia, pre-
sumably partly reflecting iron deficiency although para-
site infestation also plays a role.  In Asia 47.7%, or about 
170 millions children, were found to be anaemic.6   
 
Role of nutrition in cognitive development and cognitive 
functions 
Human brain development begins shortly after conception 
with the formation of the neural plate; cell proliferation 
and migration occurring before birth. Brain growth is 
almost finalized by the age of five, but its development, 
including: neurogenesis, synapse formation and myelina-
tion continues until late adolescence.7  The processes oc-
cur in stages with the sensorimotor cortex being the first 
to mature, followed by the parietal and temporal associa-
tion cortex and finally the prefrontal cortex that is respon-
sible for more complex functioning. Mental and motor 
skill development reflects the development of the various 
areas of the brain responsible for these skills. Sensory 
motor skills develop from birth until the age of 2; preop-
erational including verbal skills develop between 2-7 
years; concrete operational skills between 7-12 years and 
formal operational skills including logical and systematic 
reasoning between 12-15 years.8  The brain requires ade-
quate nutrition for optimum growth, development and 
maturation. Protein, fatty acids (specifically, long-chain 
fatty acids) and many micronutrients are essential for the 
proper structure of brain tissue, healthy neurochemistry, 
and the overall growth and maturation of the brain. On 
the other hand, maternal over nutrition may result in per-
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manent changes within the central appetite-regulating 
network in the hypothalamus, predisposing the offspring 
to obesity.9 Apart from nutrition, other factors such as 
poverty, socio-cultural and psycho-social risk factors also 
influence child development. 
 
Micronutrients and cognition 
There is strong evidence for the beneficial effect of iron 
and iodine supplementation on several aspects of cogni-
tive performance in children who are deficient in these 
micronutrients. Infants with iron deficiency anaemia ex-
hibited lower cognitive scores, poorer motor development 
and altered social emotional development.10 Iron defi-
ciency seems to have long-lasting irreversible effects in 
children below two years, but may have reversible conse-
quences when it occurs later in childhood.11,12  Iron is 
taken up by transferrin receptors in the endothelial cells 
and its transport through the blood-brain barrier is regu-
lated and depends on iron status.13 Iron deficiency in in-
fants affects neurogenesis, particularly the formation of 
the hippocampus and striatum, and the location and func-
tion of oligodendrites. Iron deficiency also affects neuro-
chemistry, particularly the production of dopamine.14 
Depending on the stage of brain development, iron defi-
ciency may result in a loss of brain iron that compromises 
cognitive development.  
    Thyroid hormones play an important role in neuro-
cellular proliferation, synapse and dendritic formation. 
Iodine deficiency during pregnancy causes irreversible 
neurological and cognitive deficits in the child. Maternal 
hypothyroidism disrupts neuron migration in the foetal 
brain, causing irreversible structural changes.15 At 2 years 
of age the offspring of women with hypothyroidism at 12 
weeks of gestation had delayed mental and motor func-
tioning as assessed with the Bayley Scales.16 When it 
occurs later in pregnancy, iodine deficiency may cause 
cretinism – characterized by severe mental and growth 
retardation. At a later age, iodine deficiency may limit 
development resulting in lower IQ scores.17 Cognitive 
abilities likely to be affected by iodine status are: verbal 
knowledge, non-verbal and verbal abstract reasoning, 
visual-spatial perception and executive functioning. Chil-
dren with a low iodine status perform more poorly on a 
variety of measures of cognitive performance. In a popu-
lation with high or severe iodine deficiency, iodine sup-
plementation improved the cognitive performance of io-
dine-deficient children.18  
    Zinc is essential to the central nervous system and zinc-
containing neurons are concentrated in the forebrain.19 
Maternal zinc deficiency can adversely influence foetal 
brain development. Zinc-dependent enzymes are involved 
in critical cell replication processes necessary for brain 
growth, while zinc-finger proteins are important in brain 
structure; zinc-dependent neurotransmitters in the mossy 
fibres system of the hippocampus are involved in memory. 
    B-vitamins play important roles in one-carbon metabo-
lism through the methylation and nucleotide synthesis 
pathways.20 Maternal folate deficiency is linked to neural 
tube defects, delayed intellectual development and other 
mental disorders in the offspring. Lower maternal folate 
status in early pregnancy was associated with childhood 
hyperactivity and peer problems,21 but had no impact on 
the neurodevelopment of the offspring at 5 years if the 
low status occurred in the second half of pregnancy.22 
Case reports of maternal vitamin B-12 deficiency found 
that the offspring, aged 6 months, showed developmental 
regression and cerebral atrophy which might be reversed 
by vitamin B-12 injection.23  
    Provision of multiple micronutrients showed beneficial 
effects on verbal and non-verbal abilities, including short-
term memory, attention and concentration. Meta-analysis 
of 15 studies of healthy school-aged children found that 
multiple micronutrients supplementation (most included 
iron and iodine) improved academic performance and 
fluid intelligence.24 In fact given the low cost of micronu-
trient supplementation and fortification, it has been iden-
tified as the most cost-effective solution to help alleviate 
problems associated with poverty.25 
  
Polyunsaturated fatty acids and brain development 
Long-chain polyunsaturated fatty acids (LC-PUFAs), 
especially docosahexaenoic acid (DHA) and arachidonic 
acid (ARA), are key building blocks in the brain. There is 
a rapid uptake of DHA and ARA by the infant brain, be-
ginning in the third trimester of pregnancy and continuing 
throughout the first two years of life.26 LC-PUFA synthe-
sis is inefficient in both the foetus and young infant, and a 
supply of preformed LC-PUFAs is necessary to meet the 
needs of the rapidly developing brain. During pregnancy, 
LC-PUFAs are actively transported across the placenta. 
Breast-fed infants continue to receive LC-PUFAs from 
breast milk that contains all the required fatty acids. 
However, the DHA supply to the unborn baby during 
pregnancy, and the DHA content of breast milk, may be 
low if the maternal diet does not include foods that are 
sources of preformed DHA.27-29 However, the supply of 
preformed LC-PUFAs to both the foetus and the newborn 
is highly variable.   
    Several studies have reported no effects of administer-
ing LC-PUFA supplements on measures of performance 
obtained with global tests of infant development, such as 
the Bayley Scales. However, global tests of infant devel-
opment were originally designed to detect delayed devel-
opment, and place undue emphasis on perceptual and 
motor skills, rather than important cognitive functions: 
hence, they might not adequately assess cognitive abili-
ties during the first two years of life.30,31 An alternative 
approach to the study of the effects of LC-PUFAs on spe-
cific cognitive functions is to consider information proc-
essing and problem solving. Speed of information proc-
essing in infants can be assessed by measures of visual 
attention (the duration of looking) during visual paired 
comparison or habituation tests. An observational study 
reported a significant relation between higher maternal 
DHA status at delivery, and faster infant information pro-
cessing on a test of visual habituation at 4 and 6 months.32 
Infants fed a formula supplemented with DHA and ARA 
showed faster information processing during the first year 
of life compared to infants fed a control formula.33 A sec-
ond approach is means-end problem solving that involves 
deliberately performing a sequence of actions to achieve a 
goal. Simple examples include finding a toy that is hidden 
under a cover, or pulling a cloth to retrieve an out-of-
reach toy. Means-end problem solving ability develops 
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rapidly between 6 and 12 months.34 Several randomized 
clinical trials have found that supplementation with LC-
PUFAs, especially DHA, during pregnancy and the first 
six months of life improved problem solving.35,36 Despite 
the limited number of follow-up studies, the results have 
found that the effects of LC-PUFAs on information proc-
essing extended beyond infancy to later childhood.37,38  In 
contrast, the effects of LC-PUFA supplementation on 
cognition in older children are less clear. LC-PUFAs have 
been shown to have both cognitive and behavioural bene-
fits for children with learning difficulties, such as dys-
lexia or ADHD.39 In contrast the effect of LC-PUFA sup-
plementation on normal children was limited or even had 
no effect on cognition and behaviour.40  
 
Assessment of cognitive functions in infant and young 
children 
IQ tests have widely been used and provide significant 
predictions of success in school and related outcomes.  
However, questions about dietary influences on cognitive 
development may or not be answered by general IQ 
scores, and could be most appropriately addressed by 
using specific age-appropriate cognitive developmental 
tests that are linked to underlying neural mechanisms.  
Therefore, an alternative approach to assessing cognitive 
development in infants and young children is to identify 
specific aspects of cognition and to develop valid and 
reliable techniques of measurement.41 
    Early cognitive development should focus on cognitive 
abilities, namely, memory, attention, language, and 
knowledge. Memory (defined as encoding, storage, and 
retrieval of information) can be divided on the basis of 
duration of storage (eg, short term versus long term), type 
of information stored (eg, semantic - recall of general 
facts versus episodic - recall of personal events), and ac-
cessibility to conscious awareness (eg, explicit versus 
implicit). Measurement techniques in infants and children 
include responding to novelty, learning tasks, search tasks, 
deferred imitation and delayed response. Attention refers 
to the broad array of processes that direct the sensory 
focus, and can be subdivided into relevant categories. 
Endogenous attention refers to the internal, volitional 
process through which sensory focus is directed toward 
external stimuli and can be contrasted with related aspects 
of attention (eg, maintaining alertness, orienting toward 
compelling external stimuli). Endogenous attention can 
be assessed using laboratory tasks in which the infant or 
child monitors various stimuli and it is observed how they 
respond when there is a gap or alternatively overlapping 
stimuli. Attention is also manifest in a wide array of be-
haviours so it is amenable to measurement via parent or 
care giver observation-based reports. Early language can 
be divided into production and comprehension. Multi-
word utterances lead to characterizations such as the 
mean length of utterance and the presence of various lev-
els of syntax and grammar. Language is relatively obvi-
ous and thus can be assessed using parental reports, for 
example the MacArthur-Bates Communicative Develop-
ment Inventories42 and various laboratory procedures 
such as word comprehension. Finally, knowledge refers to 
the content and organization of mental representations.  
Inferences about the child’s knowledge can be drawn 
from how the child responds to possible versus impossi-
ble physical occurrences, organizes and sorts stimuli, and 
solves problems.   
 
Adaptation of cognitive assessment tools for Asian 
populations 
Cognitive tests of Western origin may prove inadequate 
when assessing children in developing countries who live 
in multiple risk environments: nutritional, environmental, 
socio-economic, although there are also cultural differ-
ences. Cognitive test scores should be culturally appro-
priate; have a consistent construction (they measure the 
same psychological concept cross-culturally); should be 
administered in a similar way; care should be taken when 
translating items to ensure a common meaning.43    
    Three options, adoption, assembly and adaptation, are 
used to transform an instrument from one culture to an-
other.44 Adoption of an instrument is used to compare 
performance on tests across cultures. Assembly involves 
constructing a new set of measures if the existing tests are 
inapplicable in another population. Adaptation is a com-
bination of adoption and assembly, hence it involves an 
accurate translation of the reliable and valid components 
of the test combined with the substitution of parts that 
cannot be reliably applied (due to language, culture or 
psychometric properties).  
    The Kaufman Assessment Battery for Children 
(KABC-II)45 is based on a theoretical model that tries to 
gain universal validity by minimizing the influence of 
culture and language.46 An example was the use of 
KABC-II with 6-10 year-old Kannada speaking school 
children of low socio-economic status in Bangalore, In-
dia.47 The adaptation employed an iterative procedure of 
translating, piloting, and modifying instructions, exam-
ples and items.48 Child psychologists translated the test 
instructions and items from English to Kannada and the 
test was independently back translated by a psychologist 
to ensure consistency of meaning. Information about the 
children’s direct living environment was collected by 
interviewing parents and teachers. A qualitative judg-
mental approach was used to pilot test items for cultural 
appropriateness followed by the use of statistical proce-
dures to assess the reliability and validity of the adapta-
tion. In this exercise, five types of adaptation were needed, 
namely, 1) construct-driven adaptations related to differ-
ences in definitions of psychological concepts across cul-
tures; 2) theory-driven adaptations involving changes 
required for theoretical reasons; 3) familiarity-driven ad-
aptations based on differential familiarity with the task or 
item characteristics or stimulus materials; 4) culture-
driven adaptations to suit the different cultural norms, 
values, communication styles, customs, or practices; and 
5) language-driven adaptations, the unavailability of se-
mantically equivalent words across languages or from 
structural differences between languages. Unlike tests of 
general perception, many non-verbal tests are in fact cul-
turally loaded. Adaptation should also focus on response 
formats including multiple anchor points. Expertise in 
linguistic, psychometric and cultural knowledge is indis-
pensable in this adaptation process. As an example, an 
adapted version of a test was administered to over 500 
children49 and the Cattell-Horn-Carroll (CHC) model46 
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underlying the original KABC-II was largely replicated 
when tested using a Structural Equality Model. Signifi-
cant associations were found between test scores, back-
ground characteristics (age and gender) and scholastic 
achievement. Girls performed better than boys in verbal 
learning recall, verbal fluency, number cancellation time 
and coding, indicative of better fluid reasoning and the 
ability to learn tasks. Statistical analysis confirmed that 
test scores increased significantly with age and the mental 
processing index (MPI) obtained correlated significantly 
with arithmetic test results.  
 
Application of knowledge on nutrition and cognition in 
nutrition studies: Examples from Asia 
There are several studies in Indonesia/Australia, India, 
Thailand and Vietnam on the impact of nutritional inter-
vention on the cognition of children. The NEMO study 
looked at the effects of a 12-month micronutrient inter-
vention on learning and memory in well-nourished and 
marginally-nourished school-aged children, aged 6-10 
years, in Australia and Indonesia.50 The parallel random-
ized controlled trials consisted of four treatment groups of 
60 children with: 1) micronutrients (M, containing iron, 
zinc, folate, vitamin A, B-6, B-12, and C); 2) long chain 
n-3 fatty acids (FA, consisting of DHA and EPA); 3) mi-
cronutrients plus long chain n-3 fatty acids (MFa); and 
placebo (P) groups. Biochemical status was assessed at 
baseline and after a 12 month intervention, while school 
and cognitive performance was measured at baseline, 6 
months, and 12 months. In Australia, improved serum 
ferritin, body iron stores, red blood cell folate, and vita-
min B12 were found in the M group. FA treatment also 
had significant effects on the plasma levels in terms of 
EPA, DHA, and total n-3 fatty acids. A significant posi-
tive effect on their verbal learning and memory (general 
intelligence and visual attention) was only observed in the 
M group. Similarly, in Indonesia, supplementation im-
proved micronutrient status and body iron stores. Both the 
M and FA groups had increased levels of plasma DHA 
and total plasma n-3 fatty acids. However, in girls but not 
boys, the M group showed an improvement in verbal 
learning and memory, although no effect on general intel-
ligence and visual attention was observed. Fatty acid sup-
plementation had no effect on the performance of cogni-
tive tests. 
    Several nutrition intervention trials and cohort studies 
in school children were conducted by St John’s Research 
Institute in India. The ‘Champion’ study compared the 
effect of two different dosages of a combination of mi-
cronutrients and n-3 (omega-3) fatty acids on the growth 
and cognitive performance of healthy school children 
from poor socio-economic backgrounds.51 The four paral-
lel groups received foods fortified with either 100% or 
15% of the RDA of micronutrients, in combination with 
either 900 mg α-linolenic acid plus 100 mg DHA or 140 
mg α-linolenic acid for 12 month. Cognitive tests assess-
ing short-term memory, fluid reasoning retrieval ability, 
cognitive speediness, and overall cognitive performance 
were conducted at baseline, 6 and 12 months. Over a year 
in all groups, cognitive test performance improved at a 
rate about twice that expected. Overall, higher doses of 
micronutrients were as effective as lower dosages in im-
proving cognitive performance. There was no difference 
in cognitive performance between the high and low 
omega-3 fatty acid groups. The Mysore Parthenon birth 
cohort examined whether lower maternal plasma folate 
and vitamin B-12 concentrations and higher plasma ho-
mocysteine concentrations during pregnancy, were asso-
ciated with a poorer neurodevelopment of the offspring 
(long- and short-term memory, reasoning ability, atten-
tion and concentration, and visuo-spatial and verbal abili-
ties).52 The children's cognitive test scores increased by 
0.1–0.2 standard deviation per standard deviation increase 
in maternal folate levels, independent of parental and 
child demographic factors. There were no consistent as-
sociations between maternal vitamin B-12, or homocys-
teine values, and the child’s cognitive performance. 
While many factors influence the functional outcome of 
nutritional intervention in children, baseline nutritional 
status and home environment are particularly critical. The 
timing, dose and duration of the intervention and the ap-
propriateness of the test also need to be considered when 
examining the impact of nutrition on the cognition of 
children.  
    The Institute of Nutrition Mahidol University has also 
examined micronutrient intervention in children and 
pregnant women. Multi-micronutrient-fortified seasoning 
powder (1/3 of the Thai RDA of vitamin A, iron, iodine 
and zinc) was fed to school children for 32 weeks and 
resulted in a significant improvement in iodine and zinc 
status, as well as reduced respiratory-related illness and 
diarrhoea. The fortified group performed better on a vis-
ual recall task but not the digit span test.53  A second ran-
domized controlled trial evaluated the efficacy of multi-
micronutrient-fortified biscuits, with or without de-
worming, on the micronutrient status and cognitive per-
formance of Vietnamese school children.54 The fortifica-
tion significantly improved serum ferritin, retinol, zinc 
and iodine status and enhanced the efficacy of de-
worming. Multi-micronutrient fortification significantly 
improved forward digit span and Raven’s Coloured Pro-
gressive Matrices tests (CPM), especially in anaemic 
children. In a rural northeast area, at 9 years old, there 
was no significant difference on any of the cognitive out-
comes (IQ, Raven’s CPM scores) of children who had 
received iron, zinc, combined iron and zinc, or placebo 
during their infancy. Growth in both early and late in-
fancy was positively associated with intelligence (full 
scale, verbal, and performance IQ) at 9 years.55  
    Lessons learnt from these experiences include the fol-
lowing. There have been difficulties in deciding which 
cognitive tests would be appropriate when using a multi-
ple micronutrient supplement as the intervention. It was 
not possible to tease out the relative contribution of each 
of the nutrients on cognitive improvement when the in-
tervention included many micronutrients. In addition syn-
ergistic interactions between nutrients cannot be estab-
lished. Tests such as Wechsler’s Intelligence Scale for 
Children III (WISC III) or Raven Progressive Coloured 
Matrices have been widely used since they are non-verbal, 
can be translated and have been validated. However, 
when using these tests with children who may not be ex-
posed to the same environment as those in urban, more 
economically advantaged settings, lower scores may re-
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flect environmental factors rather than actual cognitive 
ability. 
 
NUTRITION, BRAIN NEURODEGENERATION 
AND COGNITIVE DECLINE IN OLDER ADULTS 
Neurobiology of cognitive decline and dementia  
Brain atrophy associated with ageing proceeds over many 
decades beginning in young adulthood. The associated 
cognitive decline accelerates in old age, but there is much 
variation in the rate of decline, reflecting the individual’s 
‘cognitive reserve’, the capacity of the brain to deal with 
the effects of disease without manifesting clinical symp-
toms. Also, distinct cognitive functions such as semantic 
memory are relatively spared by aging, but prospective 
and episodic memory in particular decline over time.56,57  
    Cognitive decline and functional disability are clinical 
symptoms of dementia, a series of syndromes that reflect 
damaged and malfunctioning neurons. The most common, 
Alzheimer’s disease (AD), accounts for between 50-70% 
of all dementias, with vascular dementia accounting for 
another 10-15%, although a considerable proportion have 
cerebrovascular pathologies, so-called mixed dementia. 
There are as many as fifty other causes that include head 
injury, drugs, alcohol, and specific nutritional deficiencies. 
Although the most widely recognized symptom of AD is 
memory loss, other mental functions including mood and 
language are also impaired. To date, therapies developed 
for AD provide non-lasting symptom alleviation, but they 
do not reverse or prevent the progression of disease.  
    The accumulation of neuritic plaques (ß-amyloid) and 
neurofibrillary tangles (aggregates of the cytoskeletal tau 
protein) are considered the histopathological hallmarks of 
AD, and such changes are known to precede the onset of 
AD by decades. Factors including oxidative stress and 
inflammation are known to play important roles in the 
ageing of the brain and hence cognitive decline. For ex-
ample, oxidative DNA damage is shown to reduce the 
expression of selectively vulnerable genes involved in 
learning, memory and neuronal survival, accelerating 
brain ageing and cognitive decline in middle age,58 and 
has been shown to occur in individuals with mild cogni-
tive impairment (MCI) and AD.59  Buccal cells of AD 
patients have shorter telomeres, components essential for 
chromosomal stability, and telomere shortening has been 
linked to accelerated senescence.60 
   
Role of nutrition in CNS neurodegeneration and cogni-
tive decline  
Given the limited effectiveness of current pharmacologi-
cal products, there is an emerging interest in developing 
therapeutic nutritional products (“neutraceuticals”) for 
dementia. Nutrition may modulate cognitive processing at 
many levels through multiple cell signalling pathways 
and various modes of action such as synaptic strengthen-
ing, neuro-protection, the facilitated release of neuro-
transmitters, vasodilation, modulation of neurotransmit-
ters (glutamate, acetylcholine, 5-HT, dopamine and 
GABA) receptor systems, and inhibition of acetylcholi-
nesterase activity. At the cellular level, nutrient deficien-
cies may result in DNA damage, reduced regenerative 
potential, demyelination and brain atrophy.61 For example, 
nutrients such as folate and vitamin B-12 are required for 
genome maintenance, and iron or copper overload can 
exacerbate homeostatic imbalance in redox pathways.62 
Malnutrition is common in the elderly,63 and marginal or 
biochemical deficiencies in micronutrients have been 
shown to have significant health effects.  
    Neutraceutical product development typically starts 
with the screening of functional ingredients for their ef-
fects on key underlying biological mechanisms associated 
with cognition. A potential ingredient is selected and mo-
lecular studies delineate their mode of action and efficacy 
using animal models, before moving to clinical trials. The 
potential of nutritional products to slow cognitive decline 
and dementia is demonstrated by a rapidly growing body 
of evidence. A review of the evidence suggested that a 
range of dietary and nutritional factors are associated with 
a reduced risk of cognitive decline and AD: they included 
vitamin E (from food), folate and vitamin B-12 (from 
food and supplements), fish at least once per week, ω-3 
fatty acids, a moderate intake of wine (1-6 drinks/week), 
consumption of fruit juices, less calories and saturated fat, 
and a Mediterranean type diet.61 
 
Folate and B-12 
The evidence is compelling for a link between vitamin B-
12, folate and cognitive functioning.61 Folate and B-12 
are intimately involved in methylation and DNA/RNA 
reactions that are critical in the biosynthesis of nucleo-
tides, membrane phospholipids and monoamine neuro-
transmitters in the brain. As folate provides the methyl 
group for the conversion of methionine to S-
adenosylmethionine (SAM), the major methyl donor for 
methyltransferase reactions, CNS hypomethylation is a 
key biochemical defect in impaired brain functioning re-
sulting from folate deficiency.64 Low vitamin B-12, folate 
and high homocysteine status are associated with higher 
DNA damage and shorter telomeres in older men.65 
Among non-demented older adults in the Singapore Lon-
gitudinal Ageing Studies cohort, low levels of serum fo-
late were associated with poorer performance on tests of 
memory, learning and language. High levels of homocys-
teine, independently of folate, were associated with defi-
cits in constructional ability and processing speed,66 and 
were also associated with a smaller cerebral white matter 
volume. A study in Malaysia also showed the association 
between cognitive impairment and poor serum folate con-
centration and DNA damage.67 
    Nutrient-gene interaction as well as epigenetic factors 
may also impact on cognitive functioning. For example, 
MTHFR gene polymorphisms in the folate pathway are 
linked to susceptibility to AD.68 The association between 
serum B-12 and global cognitive function, episodic mem-
ory and attention/working memory was significantly 
more pronounced in individuals with the APOE-e4 geno-
type, suggesting a greater susceptibility to the influence 
of variations in the level of vitamin B-12.69  
 
Long chain polyunsaturated fatty acids  
The long chain omega-3 polyunsaturated fatty acids (n-3 
PUFAs) eicosapentaenoic acid (EPA, C20:5n-3) and do-
cosahexaenoic acid (DHA, C22:6n-3) are found in high 
levels in the brain, with DHA being particularly found in 
high concentrations in deep brain structures.70 Due to the 
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inefficient synthesis of DHA from its precursor α-
linolenic acid (ALA, C18:3n-3), a supply of preformed 
DHA from food sources such as fish and shellfish is es-
sential.  
    Cell culture and animal models provide mechanistic 
support for a possible clinical benefit of DHA in AD. n-3 
PUFA may influence neural functioning through its ef-
fects on proteins/enzymes that play a role in brain mem-
branes,71 neuronal gene expression,72 and as a precursor 
of the lipoxygenase product (neuroprotectin D1) which 
promotes resolution of inflammation: together eliciting 
potent cell-protective, anti-inflammatory and prosurvival 
repair signalling.73 DHA may also promote neuronal sur-
vival via the brain derived neurotrophic factor and other 
signalling pathways.74 It also attenuates zinc transporter 
expression and reduces zinc influx into neuronal cells.75 
Finally, the neuroprotection of n-3 PUFA may be attrib-
uted to its role in blood vessel dilation and improved 
blood flow.76 Cell culture and transgenic animal models 
suggested that DHA supplementation attenuates amyloid 
and dendritic pathology in AD.77,78 Post-mortem studies 
have found lower DHA concentrations in the brains of 
AD patients.79  
    Epidemiologic studies examining n-3 PUFA intake in 
food, or the examination of blood levels, also support a 
possible beneficial role for DHA in AD. Among 11 pro-
spective, 3 cross-sectional studies and one case-control 
study that examined n-3 PUFA status (dietary intake or 
blood levels) and the risk of developing AD, one study 
showed a positive relationship between plasma phosphol-
ipid levels and risk of AD, while 2 studies demonstrated 
no significant effect, and 12 studies reported an inverse 
relationship between AD risk and n-3 PUFA status.80  
    Clinical trials of n-3 PUFA supplementation are limited 
in number and vary in the study population, dosage, prep-
aration, and exposure duration. The outcomes also vary. 
Evidence of a therapeutic effect in patients with AD is 
lacking, but the results suggest that DHA may benefit 
patients with MCI or healthy older adults with mild cog-
nitive deficits. A recent DHA supplementation study 
showed improved learning and memory functioning in 
healthy subjects with age-related cognitive decline.81 A 
smaller study showed improvement in immediate verbal 
recall with phosphatidylserine (containing omega-3 fatty 
acids) supplementation.82 However, larger randomized 
clinical trials are needed before firm conclusions can be 
drawn. 
 
Amino acids and proteins  
Proteins and amino acids play important biochemical 
roles in cognition as key component of brain cells. In the 
brain, proteins function as receptors, ion channels and 
transport mechanisms, and about half a dozen amino ac-
ids function as promoters or precursors of neurotransmit-
ter synthesis. Tryptophan is an essential building block 
for serotonin whereas phenylalanine and tyrosine are 
building blocks for dopamine, epinephrine and norepi-
nephrine, and glutamine/glutamic acid is a building block 
of gamma-amino butyric acid (GABA). It has been con-
sidered whether dietary amino acids and proteins are ca-
pable of affecting cognitive functioning by influencing 
the availability of these substrates.  
    There is, however, limited evidence to support any 
clinical effects of providing amino acids and peptides. 
The cognitive effects measured in generally well-fed and 
healthy populations have been unconvincing, and often 
contradictory. Under normal conditions, dietary intake 
has little/no effect on synaptic amino acid pools.83 How-
ever, in abnormal situations when regulatory controls are 
disrupted, dietary amino acids may be influential.84,85 
Increasing evidence suggests possible cognitive benefits 
from consuming very short peptides, such as carnosine, 
which is naturally present in the human brain and readily 
passes through the blood-brain barrier. A possible neuro-
protective and anti-AD property of carnosine has been 
suggested86,87 by its ability to detoxify advanced glycation 
end products that may otherwise alter neural structures 
and facilitate pathological neuro-degeneration.88 
 
Functional food ingredients and herbal substances 
As cognition involves multiple processes, interacting in 
complex and possibly idiosyncratic ways, it may not be 
surprising that single agents have little impact on cogni-
tive decline and dementia. Unlike mainstream pharma-
cological agents, nutraceuticals and herbal medicines - 
‘nutra’ - typically contain dozens of active phytochemi-
cals. It is possible that by acting in concert on multiple 
systems (neuronal, metabolic and hormonal), ‘nutra’ 
agents may offer a promising approach. Since behav-
ioural processes are themselves modulated by multiple 
systems, the effects of herbal extracts may particularly 
depend upon complex interactions within and between 
biological systems.  
    The plant polyphenols in tea (Camellia sinensis) are 
catechins, including epigallocatechin gallate (EGCG) in 
fresh green tea, and their oxidized polyphenolic com-
pounds, theaflavins and thearubigins, formed during fer-
mentation in black tea (fully fermented) and Oolong tea 
(semi-fermented). The well known anti-oxidant properties 
of tea polyphenols are not altered by fermentation.89 The 
neuroprotective effect associated with EGCG may be 
attributed to its antioxidant and iron-chelating properties, 
in addition to modulating cell signalling and cell survival 
pathways.90,91 As well, EGCG has been shown to reduce 
Aβ generation by promoting α–secretase cleavage of am-
yloid precursor protein (APP),92 and both black tea and 
green tea inhibit human acetylcholinesterase activity.93 
Other phytochemicals such as theanine, which is an ami-
no acid uniquely found in tea leaves, also show neuropro-
tective effects.94 Recent epidemiological studies in elderly 
populations in the Japanese Tsurugaya Project95 and the 
Singapore Longitudinal Ageing Studies96 have observed 
that a higher consumption of green, black and oolong tea 
was associated with a lower prevalence of cognitive im-
pairment and decline, as well as better performance on 
several tests of cognitive functioning, effects not similarly 
observed with coffee drinking.  
    Blueberries, walnuts or other fruits and vegetables that 
are rich in phytochemicals have been shown in animal 
models to slow or reverse deficits in spatial memory and 
learning.97 The mixture of polyphenols may have a syner-
gistic reaction, as fractions of the blueberry polyphenols 
are less effective than blueberry juice. Brain localization 
studies have shown that anthocyanins are able to pass 
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through the blood-brain barrier and become localized 
within the brain in areas such as the hippocampus, frontal 
cortex and striatum that are important for learning and 
memory. The anthocyanins level in the brain has also 
been associated with cognitive performance.98 Dietary 
supplementation with blueberry appears to promote hip-
pocampal neurogenesis by increased dendritic growth,99 
while walnut supplementation appears to increase resis-
tance to oxidative stress and inflammation by decreasing 
the number of activated microglia in the aged hippocam-
pus. Preliminary clinical data in humans suggested that 
blueberry supplementation improved verbal memory and 
word list recall in older adults with an early onset mem-
ory decline.100 
    Found in curry spice (turmeric), curcumins have strong 
anti-inflammatory and anti-oxidant properties. Recent 
experimental studies have shown that curcumins in the 
diet reduce plague deposits in the brains of transgenic AD 
mice.101 In the Singapore Longitudinal Aging Studies 
subjects, regular curry intake was found to be associated 
with better cognitive performance.102 There remains a 
need for randomized controlled trials to generate defini-
tive evidence to support the beneficial effects of nutri-
tional factors in preventing dementia. 
    Functional MRI studies showed that flavonoid-rich 
cocoa intake increased localized brain activation in the 
dorsolateral prefrontal cortex, anterior cingulate and pa-
rietal cortex, coinciding with peak serum flavanol, al-
though there was no improvement in task performance.103 
Cross-sectional epidemiological data suggested that a diet 
high in cocoa is associated with better cognitive abili-
ties,104 but a randomized controlled trial of the short-term 
(6 weeks) effects of dark chocolate and cocoa failed to 
show a beneficial effect on neuropsychological function-
ing.105  
 
Panax ginseng  
Both laboratory and clinical studies strongly suggest that 
Panax ginseng may have beneficial effects on cognitive 
performance. Recent evidence demonstrated that Panax 
ginseng can directly modulate neuronal activity as evi-
denced by the improvement in the electroencephalograph 
(EEG) profile.106 Randomized controlled trials with het-
erogeneous outcome measures, trial duration, and ginseng 
dosage, suggested improvements in working memory, 
behaviour and quality of life.107,108 
    Salvia (sage) is recognized in Ayurvedic, Chinese and 
European medicine as having beneficial effects on the 
brain, nerves and memory. Besides its anticholinesterase 
properties, salvia shows anti-oxidant, pro-oestrogenic and 
anti-inflammatory properties. A small number of trials 
using extracts of S. lavandulaefolia and S. officinalis have 
shown improved memory and attention in healthy older 
volunteers,109 and in patients with mild to moderate 
AD.110 
 
Methodological issues in clinical trials of nutrition and 
cognition in older persons  
The fact that age-related cognitive decline is known to 
vary widely among individuals, and take place over an 
extended period from early in life, has important implica-
tions for experimental designs. A preponderance of evi-
dence thus rests on epidemiological data that must meet a 
range of strict criteria to demonstrate causality. The abso-
lutely essential criterion is that exposure must preceded 
the outcome. Causality is more likely if the relationship is 
strong; there is a dose-response relationship; results have 
been replicated in different settings using different meth-
ods; the suggested effects are plausible and agree with 
accepted understandings of pathology; and finally, alter-
native hypotheses have been ruled out. 
    Information from randomized, double-blind, placebo 
controlled studies, nevertheless, is highly desirable given 
their ability to establish causality. Large samples and 
long-term studies are required, especially if gross out-
comes such as a clinical diagnosis of dementia or global 
cognitive performance such as the Mini Mental State Ex-
amination (MMSE) are used. In this regard, more sensi-
tive cognitive tests that selectively measure specific do-
mains of cognitive functioning are expected to better 
track subtle changes over relatively shorter time periods. 
Usually, it is necessary to employ a range of tests care-
fully selected for their validity, sensitivity, level of diffi-
culty, reliability and ease of administration.  
    Each study thus calls for a customized approach, taking 
into account the specific aims (what needs to be substan-
tiated), product characteristics (what seems appropriate to 
measure?) and target population (what is feasible to 
measure?).111 There is no “one size fits all” battery of 
cognitive tests, and even “off-the-shelf” assessment tools 
need to be tailored to the target groups. Attention to test 
planning and administration that takes into account stan-
dardization of procedures, minimizing confounding fac-
tors, such as subject’s mental state and the testing envi-
ronment, potential learning and practice effects, have an 
important impact on the quality of the data. The evalua-
tion of effect specificity, interaction between cognitive 
domains, speed-accuracy trade off, time on task(s) and/or 
test(s) and the potential role of compensatory effort (in-
creased effort to cope with less efficient brain functioning) 
contribute to the correct interpretation of the effect of the 
nutritional intervention on cognitive functioning. An in-
terdisciplinary approach from diverse perspectives of 
behavioural, nutritional and biological sciences is vital for 
credible results.  
    The alternative approach to measuring cognitive de-
cline is to use a biomarker that detects a neuropathologi-
cal feature with a proven relationship to neuropathologi-
cally confirmed AD cases, that is reliable, non-invasive, 
simple to perform and inexpensive.112 As cognitive aging 
involves various biological mechanisms such as oxidative 
stress, inflammation, homocysteine and advanced glyca-
tion end products that can be modified by nutritional fac-
tors, such biomarkers of cognitive ageing may be useful 
to measure a cognitive response to dietary or nutritional 
interventions. As a case in point, beta-amyloid and Tau 
protein measurements in cerebrospinal fluid are currently 
recommended, but are invasive and not acceptable to all 
participants.  
    Another approach is to use brain imaging techniques 
for global or regional volumetric measurements, such as 
of the hippocampus and entorhinal cortex that are known 
to be associated with mild cognitive impairment (amnes-
tic MCI) and early AD.112 Brain imaging techniques using 
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Pittsburgh Compound B (PiB) may be used to measure β-
Amyloid deposition, a hallmark of AD pathology.112 
However, the known inconsistency between biological 
measures and clinical symptoms should be noted; at post-
mortem individuals with extensive AD pathology may 
display few or no symptoms before death.113 However, in 
the Australian Imaging, Biomarker and Lifestyle (AIBL) 
Flagship Study of Ageing, a positive PiB scan indicating 
high Aβ burden was present in 67% and 98% of MCI and 
AD participants, respectively.114 However, high Aβ bur-
den was also found in 31% of healthy controls although 
the percentage increased with age; 18% of healthy con-
trols aged 60-69 had high PiB binding, rising to 65% in 
those over 80 years. A positive PiB scan in persons with 
MCI is the strongest predictor for cognitive decline and 
conversion to AD;112 46% of MCI cases with positive PiB 
status at baseline converted to AD, as compared to 16% 
in negative PiB subjects. Altogether, a combination of 
imaging measures and biomarkers that are translatable 
into behavioural effects may be necessary.  
    The heterogeneity of the nutritional interventions and 
measured endpoints is an important consideration. De-
mentia is a symptom that may reflect many different dis-
eases, such that different aetiologies mean that nutritional 
intervention will impact in different ways in different 
individuals. For example because the Wernicke-
Korsakoff syndrome responds to thiamine supplementa-
tion, and vitamin B12 deficiency responds to supplemen-
tation of this vitamin, does not imply similar benefits oc-
cur for other forms of dementia.  
    With some products experience showing that many 
cognitive effects are dose dependent, but the highest dose 
does not necessarily provide the greatest effectiveness. 
Complex dose-time-task interactions, and the dissociation 
of acute versus chronic effects, need to be addressed with 
the appropriate methodology. In interventions involving 
herbal extracts, it is important that the extract is standard-
ized and well characterized for findings to be reproduci-
ble. The underlying mechanistic link will need to be in-
vestigated using biomarkers and the examination of re-
ceptor and enzyme functioning. 
    With regards to the target population a potentially fruit-
ful way of increasing sensitivity is to study those who are 
at increased risk of developing dementia, such as those 
with genetic polymorphisms (particularly the APOE-e4 
allele), lifestyle, behavioural and cardio-metabolic risk, or 
are displaying early symptoms (such individuals with 
MCI). A criticism of this approach is that these individu-
als may have already minor brain degeneration and ar-
guably nutritional intervention studies should aim at pre-
venting rather than treating cognitive decline, studying 
those of a younger age whose brain functioning can still 
be modulated. Further investigations with other genes and 
gene-nutrient interactions are needed.  
    Given the historical use of many functional ingredients 
in Ayurvedic or traditional Chinese medicine, Asia offers 
a boundless potential for investigating a role for novel 
nutritional interventions in cognitive functioning. More 
information, however, needs to be established concerning 
these natural ingredients, especially with regards to their 
toxicity, safety and clinical efficacy. Nutritional product 
development needs to address challenges in identifying 
and targeting the multiple pathways stimulated by indi-
vidual active components, as well as the complex interac-
tion between multiple components found in these natural 
products. There is also a need to demonstrate clinical 
safety and efficacy for specific populations, together with 
product stability, palatability, packaging and affordability. 
    There are pertinent considerations for conducting nutri-
tional and cognitive research in Asia. There should be 
careful understanding of the socioeconomic and educa-
tion background of the population of interest. With re-
gards to the use of MMSE for assessing global cognitive 
performance, unique differences in MMSE scores have 
been shown among Chinese, Malays and Indians, and by 
educational level among older Singaporeans.115 Thus, 
stratification by education and ethnicity should be part of 
the study design. Similarly variations by gender or educa-
tion may or may not be present for particular cognitive 
tests: such difference should be explored in initial studies.  
 
EVIDENCE-BASED CLAIMS AND CONSUMER 
UNDERSTANDING  
It is important that the evidence on the role of nutrition on 
cognitive functioning is clearly communicated to the gen-
eral public. One way is the use of a health claim, which is 
intended to provide factual information of health related 
properties of certain foods, nutrients and bioactive sub-
stances, for the purpose of guiding the consumer to make 
healthy food choices. A claim needs to be both scientifi-
cally defensible and able to communicate the intended 
meaning to the general public. In turn regulators require 
appropriate and substantial evidence for claims in the area 
of nutrition and cognition that are specific, quantifiable 
and related to specific target groups. 
    The current status of health claims in the area of nutri-
tion and cognition in various regions of the world are 
considered. Topics covered include the existing regula-
tory framework, the review and substantiation process, 
and the evidence required. The industrial perspective is 
discussed using the role of docosahexaenoic acid (DHA) 
for cognitive development as a case study. The consumers 
understanding of the role of nutrition in cognitive func-
tioning is also examined as the nature of the consumer 
understanding should be taken into account when examin-
ing such claims. It is important to ensure that the word-
ings of the claims are correctly understood by consumers.  
 
European perspective 
In December 2006, the European Union adopted a new 
regulation concerning nutrition and health claims made 
about foods. Article 13.1 of the regulation refers to ‘gen-
eral function’ health claims, which includes psychological 
and behavioural functions.116  Article 14 of the regulation 
refers to claims involving disease risk reduction, child 
development or health.117 The European Food Safety Au-
thority (EFSA) is responsible for verifying the scientific 
substantiation of submitted claims.  
    Claims submitted under Article 13.1 have a format 
which specifies the food constituent (eg Vitamin B-12, 
Tryptophan), the health relationship that is the subject of 
the claim (eg ‘cognitive function’, ‘attention’), proposed 
wording for the claim (eg ‘improves concentration’, ‘en-
hances memory’), conditions of use (eg ‘food supplement 
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with 75-225 mg in the daily dose’), and target population.  
The submitted claim must provide a list of scientific arti-
cles to support the claim.   
    Under the EFSA panel, the working sub-group for 
mental and nervous system claims developed the methods 
and procedures for reviewing claims involving psycho-
logical, behavioural and neurological functioning. The 
protocol involves: initial screening to establish whether a 
claim meets the basic criteria for review; assessing 
whether the claimed effect is beneficial to human health; 
identification of the target population; and evaluation of 
the scientific evidence. 
    There are several steps in the initial screening protocol. 
First, the food constituent needs to be adequately charac-
terized; this would be a challenge in the case of herb ex-
tracts containing unspecified substances. Second, the 
health relationship defined in the context of proposed 
wording must be meaningful and measurable. Claimed 
effect on memory, attention/concentration and resistance 
to stress would meet these criteria while general terms 
such as cognitive functioning or mental performance 
would be too vague and cannot be specifically measured. 
Third, the conditions of use of the food constituent must 
be adequately specified (e.g. quantity required to achieve 
the claimed effect). And lastly, there must be scientific 
evidence obtained from human studies. Only applications 
that pass the initial screening are reviewed.   
    Assessment is also made as to whether the claimed 
effect is beneficial to human health. The majority of 
claimed effects (eg improving memory) are beneficial, 
but others may not be, for example, the enhancement of 
alertness/arousal might not be beneficial if it reaches a 
position of being perceived as anxiety. Target populations 
also need to be identified. When it is not specified, the 




Food Standards Australia New Zealand (FSANZ) is cur-
rently working on a new health claims standard which 
will regulate nutrition content claims (statements about 
the presence or absence of a nutrient, energy or a biologi-
cally active substance in the food), general level health 
claims (claims about the effect of a nutrient or substance 
in a food on a health function or a non-serious disease), 
and high level health claims (claims about the effect of a 
nutrient or substance in a food, that make reference to a 
serious disease or biomarker of a serious disease).118 
Claims will have to be scientifically substantiated and not 
misleading. Meanwhile, health claims are currently regu-
lated by a transitional Standard 1.1A.2; under this stan-
dard, the only health claim that can be made about a seri-
ous disease is a claim on the benefit of maternal folate 
consumption in reducing the risk of having a baby with a 
neural tube defect.119 
    Maintaining functional capacity is essential over the 
life course, beginning with optimal growth and develop-
ment, maintaining the highest possible level of function-
ing in midlife and finally preventing disability and main-
taining independence in older life.120 Scientific substan-
tiation using peripheral approaches has been used in a 
number of cases, for example, in the development of die-
tary strategies to reduce cholesterol. We can learn from 
this type of approach when studying the role of nutrition 
in the brain, whether for sustenance or in a disease state.  
    Some understanding of the relation between nutrition 
and lifestyle and the brain has been provided by the Aus-
tralian Imaging, Biomarkers and Lifestyle (AIBL) Flag-
ship Study of Ageing. In addition, a systematic review on 
diet, physical activity, mental activity and social engage-
ment in the prevention of dementia that is being under-
taken and headed by CSIRO Preventative Health Flagship 
in Australia, will be able to provide insights. The findings 
of a review of traditional herbal medicine for dementia 
has been published.121   
    Understanding the pathology of AD also provides use-
ful information. The amyloid hypothesis postulates that 
amyloid beta (Aβ) deposits are the fundamental cause of 
AD.122 Fragmentation of Amyloid precursor protein (APP) 
produces mis-folded peptides that form into sheets that 
eventually aggregate to form fibrils, the accumulation of 
which create plaques. Intervention is potentially possible 
at several stages of this pathway: secretase inhibitors pre-
vent amyloid production; plaque formation inhibitors 
prevent amyloid aggregation; amyloid clearance promot-
ers; anti inflammatory compounds or antioxidant alleviate 
neural toxicity. Some of the known fibril inhibitors and 
distruptors are epigallocatechin-3-gallate (EGCG), cur-
cumin, resveratrol and melatonin. They generally possess 
phenolic structures and may have the potential to inhibit 
the formation of amyloid fibrils. 
    Another important aspect of scientific substantiation 
would be the ability to monitor amyloid fibril formation. 
Real time monitoring of the fibril formation has been pos-
sible using Thioflavin T as ThT binds to amyloid fibrils 
and enhances its fluorescence emission.123 Screening of 
food/plant extracts for potential Aβ fibril inhibitor/ dis-
ruptor properties is also possible using TEM imaging to 
examine whether extracts could prevent Aβ42 fibril-
logenesis and oligomerization or the disaggregation of 
preformed Aβ42 fibrils.124 
 
Japan perspective 
In Japan the function of food is divided into nutritional 
functions (primary), sensory functions (secondary) and 
psychological functions (tertiary). A functional food is 
defined as one with a tertiary function. In 1991, a regula-
tion on Foods for Specified Health Uses (FOSHU) was 
established. Under a revision of the system in 2005, foods 
with health claims consisted of those concerning nutrients 
(involving 12 vitamins and 5 minerals) and FOSHU. The 
latter in turn is made up of standardized FOSHU, quali-
fied FOSHU and disease risk reduction claims. The num-
ber of approved FOSHU products increased to a total of 
approximately 1,000 in September of 2010. 
    The existing FOSHU can be categorized into eight 
groups according to the health claim, including gastro-
intestinal conditions, blood pressure, serum cholesterol, 
blood glucose, the absorption of minerals, blood fat levels, 
tooth and bone health. An approval system has been in 
place to systematically evaluate each application by an 
expert committee under the Consumer Affair Agency and 
Food Safety Commission. The requirements of the Japa-
nese FOSHU approval system are basically similar to 
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those of the Codex guidelines and to the regulations on 
the substantiation of health claims in the EU and US. The 
main criteria include: health claims should primarily be 
based on evidence provided by well-designed human in-
tervention studies; the totality of the evidence should be 
identified and reviewed; effective components should be 
characterized by appropriate methods. 
    There are currently no FOSHU claims relating to cog-
nitive functioning. Some possible reasons for difficulties 
in obtaining such approvals include: a lack of agreement 
of the meaning of a measure and the measurement proc-
ess, the consistency of the health claim wording with the 
results of human studies and the magnitude of any differ-
ences from the placebo. Cognitive function-related topics 
under study by Japanese researchers include the preven-
tion of memory loss (eg effects of DHA on cognitive 
function in elderly people), improvement of sleep quality 
(eg effect of glycine on sleep in healthy people), and re-
covery from fatigue.  Such claims could come under the 
category of improving physiological function and organ 
functioning or causing short-term changes in bodily func-
tioning. 
 
Southeast Asia region perspective 
There is considerable interest amongst health profession-
als and the food industry in the Southeast Asia Region in 
making health claims related to the ability of nutrients 
and other food components to improve mental or cogni-
tive performance, learning capability and brain growth 
and development. This is evident from media articles, 
advertorials and advertisements dealing with such “func-
tional” claims. The nutrients or food components in-
volved include several polyunsaturated fatty acids (espe-
cially DHA and AA), sialic acid, tryptophan, taurine, 
phospholipids, iron, choline, zinc, “antioxidants”, and 
even proprietary components. These claims are targeted 
mainly at children but also mention adults. The lack of 
enforcement of regulations related to unsubstantiated 
claims, especially those in advertisements, is a concern 
that needs to be addressed.  
    There are few officially approved health claims in the 
Southeast Asia region.125 Malaysia has only one approved 
“function” claim: “sialic acid is an important component 
of brain tissue”. This claim is only permitted for use in 
infant formula and follow-up formula. Singapore also has 
a few functional claims related to foods for infants and 
young children: “choline helps support overall mental 
functioning”, “DHA, AA are important building blocks 
for development of the brain and eyes in infant” and “tau-
rine helps to support overall mental and physical devel-
opment”. Nevertheless, most authorities in the region do 
provide opportunities for the food industry to apply for 
functional claims that relate nutrition and cognitive func-
tioning. There are processes and systems in place to allow 
the review of such applications by relevant experts ap-
pointed by the authorities. Information required to be 
submitted include the proposed wordings of the intended 
claim and its scientific substantiation. The proposed 
wordings of the intended claims have to be specific, clear 
and focused. Catchy wordings that attract consumers may 
be too broad and difficult to measure. Data to support the 
claim should preferably be from human intervention trials. 
The intended claims must be measurable using specific 
parameters. The proposed claim wordings must be based 
on, and match, findings obtained from scientific studies. 
    Methodologies used to provide substantiation must be 
appropriate for the intended claim. Methodologies for 
measuring mental and cognitive performance are particu-
larly challenging and have to be socio-culturally appro-
priate for the population to which the product is directed. 
In addition, in the case of specific nutrients or food com-
ponents that are not in the current permitted lists, applica-
tions have first to be approved to allow the use of such 
ingredients.  
 
Industry perspective – DHA as a case study 
DHA is a nutritional product investigated for over a dec-
ade for its potential importance in cognitive development. 
Pure forms of DHA have been developed, on a large scale, 
through fermentation processes using micro-fungi and 
marine algae, and are used for various purposes including 
inclusion in infant formula. Clinical trials have been con-
ducted around the world to establish the efficacy of DHA.  
    A review of 873 brain-platform global new products 
showed a significant number of them included DHA 
(36.2%), taurine (25.8%), choline (25%), and omega 3 
(7.1%) in their formulation.126 Building the case for the 
addition of DHA to infant formula for the development of 
the central nervous system has not been easy. Human 
requirement for DHA has only been established recently. 
Educating the consumer takes time and is often con-
founded by misleading messages. Awareness of the sug-
gested benefits of DHA varies with different countries 
with China and Japan being most aware. DHA is mostly 
linked to heart health and less to eye and brain function-
ing. There is, however, recognition that diets deficient in 
DHA will have an impact on cognitive abilities.127 
    There are several reasons for the addition of DHA to 
infant formula. DHA is found in human breast milk at 
varying levels.29 The WHO/FAO agreed that it has con-
vincing evidence of benefits for brain and visual devel-
opment in infants.128 DHA has been recommended for 
pregnancy and during lactation by health authorities in 
England, France, Netherland, Australia, and the US Insti-
tute of Medicine. During gestation, DHA is preferentially 
transferred across the placenta to the developing foetus. 
The presence of DHA in breast milk is often cited as a 
possible reason why breast fed babies have better cogni-
tive functioning than those fed with a formula without 
DHA.129  A consensus statement suggested that pregnant 
and lactating women should have an average dietary in-
take of at least 200 mg DHA/day.130 No DHA supplemen-
tation studies of infant and children have reported adverse 
effects on development and cognition. With regards to 
maximum intake, a cohort study showed that consuming 
1 – 7.5 g/day of DHA had no adverse response.131  
    The USA has authorized “Structure/Function” claims 
for DHA. For most of the world, the obligation is on the 
manufacturer to be able to back up any on-pack claim. the 
European Food Safety Authority has given positive opin-
ions on DHA in relation to the maintenance of normal 
brain function under Article 13; in order to bear the claim 
foods should contain 250 mg of DHA in one or more 
servings.132 For a claim related to brain development it is 
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considered in relation to child development under Article 
14, but EFSA opinions to date have been inconsistent. 
 
Consumer understanding 
There is a dearth of studies of consumer perceptions of 
the association between nutrients in specific foods or in 
supplements and brain health, cognition or mental alert-
ness. Available data are limited to a few examples at dif-
ferent life stages.  
    In pregnancy, folic acid has been linked to neural tube 
defects (NTD). A survey on the knowledge and use of 
folic acid among 300 Irish women attending ante-natal 
clinics showed that 92% of respondents had heard of folic 
acid, whereas 67% knew it could prevent NTD; 30% had 
been advised to take it around conception but overall only 
18% did. 133 A similar survey among 300 UK women also 
showed that 91% of respondents knew folic acid could 
prevent NTD but only 44% took it around conception; 
knowledge about the correct timing of folic acid intake 
was seen in 76%.134 It is apparent that folic acid aware-
ness has not been accompanied by a corresponding in-
crease in its consumption. In the US, a survey showed 
that 61% were aware of the association between folic acid 
consumption and a reduced risk of brain damage/NTD, 
although only 37% of respondents consumed and 43% 
expressed a likelihood of consuming folic acid.135  
    A US survey also showed that 72% of respondents 
agreed that specific foods or beverages can improve men-
tal performance.135 Using caffeine as an example, when 
asked the reason for consuming caffeinated food/ bever-
ages, most participants (58%) consumed them for the 
taste; to stay awake/wake up (50%) and to increase con-
centration (10%). They also agreed that caffeine helped to 
stay awake/wake up (61%), increased energy (49%), im-
proved mental performance (28%) and reduced the risk of 
brain and/or nerve disease such as AD or Parkinson’s 
disease (11%).136 In the case of omega-3, 72% were 
aware of an association between omega-3 consumption 
and cognitive development with 46% currently consum-
ing and 42% expressing a likelihood of consumption. 
    Among Europeans, labels were important as a source 
of nutritional information. Participants also indicated that 
magazine/news articles played an important role in addi-
tion to health related materials. In the USA, the most in-
fluential source of information is the health professional 
(52%), followed by a dietitian (36%), health association 
(28%), food label (23%) and internet (20%).135 Looking at 
the information available online, a quick analysis of the 
first 30 websites found in response to the term “brain 
food”, produced the following list in descending order of 
the frequency of being mentioned: nuts, salmon, berries, 
flax seeds, eggs, leafy green vegetables, whole grain, co-
coa, green tea, and coffee. While there is no guarantee of 
the accuracy of information available online, many con-
sumers refer to it. 
    A survey of consumer responses to labelling health 
information in China and Malaysia showed that consum-
ers were motivated by short term benefits and had limited 
understanding that the impact on health of food choice is 
generally long term and cumulative. They also did not 
distinguish between nutrition/health information based on 
scientific evaluation and traditional folk wisdom.137 Edu-
cational institutions, medical practitioners and other 
channels such as the internet, TV, radio, newspapers and 
word of mouth were reported as information sources for 
both traditional and scientifically substantiated food-
health associations. In summary there is very little con-





Those unfamiliar with cognitive testing sometimes hope 
for a standard test battery that can be used universally.  It 
is unfortunately a largely unrealistic request. Anybody 
who looks for an analogy between cognitive testing and 
for example a biochemical assay fails to understand the 
nature of psychological functioning. One can reasonably 
expect that given the same conditions of substrate, tem-
perature, pH and other relevant parameters, within meas-
urement error a biological assay will generate reproduci-
ble results. In contrast no two samples of human beings 
will be the same, and no one sample will be the same on 
two occasions. It should, however, prove possible to pro-
duce reproducible findings when large enough groups are 
considered and obtained from similar populations, al-
though the results will be an average of a population 
rather than a statement about any individual. Even this 
assumption assumes that we understand all the variables 
that influence a particular aspect of the human condition 
and we can therefore specify the nature of the population. 
Human behaviour reflects a lifetime’s individual experi-
ences that vary on a multitude of dimensions, many of 
which are difficult to measure retrospectively and about 
which we are unlikely to be aware in many instances. 
    Cognitive functions have been categorized as falling in 
six main areas: executive functioning, memory, attention, 
perception, psychomotor and language skills. In turn, 
each of these domains can be subdivided. In addition the 
performance of each will reflect motivation, mood, fa-
tigue and factors such as the time of day as functioning is 
influenced by circadian rhythms. Tests need to be tailored 
to the population being studied. A particular test may be 
so difficult that almost nobody is able to get more than a 
few correct answers. Motivation can suffer so that the 
performance on unrelated tests also declines. Equally a 
test can be so easy that most approach maximum scores 
and therefore there is an inability to distinguish perform-
ance. When considering dementia there is a particular 
problem in that ability changes with the stage of the dis-
ease: as such many forms of a test will be required that 
reflect the degree of pathology. Similarly with children 
cognitive capacity changes with age, such that a range of 
tests will be required if they are monitored over several 
years, or a sample contains children of a range of ages. 
    Although cognitive tests attempt to measure only one 
aspect of cognition, the integrated nature of human func-
tioning ensures that this can never be fully achieved. For 
example a test of memory inevitably also reflects percep-
tion, attention, mood, motivation and depending on the 
task may also use language skills and strategic planning. 
Any study of a nutritional intervention that uses only one 
cognitive test will inevitably be unable to establish 
whether any significant difference on, for example a 
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memory test, reflects memory as such, rather than an in-
ability to sustain attention, motivation or mood. It is sur-
prising that many very expensive large scale and long 
term trials have failed to give the attention required to 
understand the nature of any cognitive changes. Because 
the test is categorized as a test of memory it cannot be 
assumed that any difference necessarily reflects a change 
in memory as such. Only a battery of well chosen tests 
will allow the profile of changes in cognitive functioning 
to be interpreted. 
    An illustration of the problems that result from not 
carefully considering the choice of tests is offered by the 
Mini-Mental State Examination (MMSE) 138 that has been 
extremely widely used when considering age-related cog-
nitive decline. An assessment is made under various 
headings: 1) Orientation – where are we; 2) Memory – 
repeat the names of three objects; 3) Calculation – count 
backwards by removing seven from a starting number; 4)  
Language – repeat a tongue-twister; 5) Perform a three-
stage instruction – place paper in the right hand, fold it in 
half and put it on your knee. 
    The widespread use of this test has without doubt 
greatly inhibited the study of the influence of nutrition on 
the aging process. The test is crude and combines into one 
score many aspects of cognition that are not similarly 
related to the aging process. The test was never intended 
to be used to study short-term responses to nutrition but 
rather was conceived as an initial everyday means of clin-
ically screening for dementia. In fact the MMSE has been 
found to correctly distinguish those with dementia on 
only 65% of occasions and four items have been found to 
detect the disorder as well as the full test.139  Although the 
ultimate criterion is the development of dementia it is 
arguably not sensible to use this as the dependant variable 
in intervention studies; unless that is the studies have ex-
tremely large samples that have been studied for very 
long periods. The incidence of dementia at age 65 years is 
1% and at 85 years it is still only 25%. As the majority of 
the population do not suffer with dementia, studies will 
need extremely large samples to pick up any dietary in-
duced changes in dementia as such, given that the vast 
majority can be expected not to develop the condition 
irrespective of the nature of the nutritional intervention. 
Although those suffering with dementia will tend to per-
form such tests poorly, the MMSE is unable to measure 
early signs of cognitive decline, changes associated with 
normal aging or alternatively subtle improvements. It 
simply lacks the needed sensitivity and the ability to dis-
tinguish those aspects of cognition that decline with age 
from those that do not. It has been suggested that when 
examining age-related changes, and there is insufficient 
time and resources, that a comprehensive test battery 
should be used. In particular attention should be directed 
to the assessment of episodic memory as this aspect of 
cognition is particularly associated with dementia and the 
early stages of cognitive decline.56  Episodic memory 
involves memory for events associated with particular 
times and places, events that can be verbally described. In 
contrast semantic memory (the meaning of words, and 
other conceptually-based knowledge that is not related to 
an individual’s specific experiences) and procedural 
memory (for example remembering how to ride a bike) 
do not decline in the same way in those with dementia. 
 
The timing and duration of dietary intervention 
Although advancing age is a predictor, an advanced age is 
not inevitably associated with dementia and there is in-
creasing interest in those who retain their faculties. Nutri-
tion is believed to be an important factor and if we under-
stand the role played by nutrition we may be able to in-
fluence the rate that dementia occurs, or the age or speed 
at which the decline begins. The mechanisms believed to 
underlie biological aging are potentially susceptible to the 
nutritional status, including oxidative stress, homocys-
teine, inflammation and advanced glycation end-points.  
However, the evidence from intervention trials has been 
disappointing. For example, a systematic review of mi-
cro-nutrient supplementation noted that although observa-
tional data suggested a link between micronutrient intake 
and health outcomes, the evidence from large randomized 
controlled trials did not support the use of antioxidant 
micro-nutrients for cardiovascular, cancer, eye health, 
immune and cognitive end points.140 Why then has there 
been a failure to demonstrate a beneficial influence for 
anti-oxidant supplementation when oxidative stress is 
thought to damage tissue? One answer is that to date stud-
ies have failed to acknowledge the time scale over which 
diet has an impact. We need to consider both whether 
there are critical ages when diet is particularly influential 
and in later life the duration necessary for a dietary inter-
vention to have an influence. 
    There is increasing interest in cognitive reserve; that is 
the capacity of the brain to sustain the effects of disease 
without manifesting clinical symptoms. Some individuals 
with extensive degeneration of the brain will display few 
memory problems; others with limited pathology will 
have extensive problems of memory. Those with larger 
brains and more neurons are better able to resist the bio-
logical changes associated with dementia.113 It is usual to 
distinguish the role played by a bigger brain (brain re-
serve) from how it has been programmed by education 
and other life experiences. As an illustration of this phe-
nomenon, in the United Kingdom a study of a birth cohort 
found that cognitive ability at fifteen years of age had 
greater influence than education on later measures of 
cognitive decline.141  Similarly, in a Scottish cohort, a 
higher incidence of late-onset dementia occurred in those 
with lower intelligence scores in childhood.142 This type 
of finding suggests that one approach to decreasing de-
mentia should be to consider the impact of diet on brain 
development, to ensure as much surplus capacity as pos-
sible. That is we should try to increase ‘cognitive reserve’. 
    The brain grows rapidly during the last trimester of 
pregnancy and the first two years of life, placing demands 
on the diet to provide the nutrients necessary for brain 
development. Inadequate levels of protein, energy, iron 
and iodine at this critical stage of brain development re-
sult in brain damage and a life-long decrease in cognitive 
ability.143 Although such clinical deficiencies clearly have 
permanent consequences, it cannot be assumed that rela-
tively small changes in the diet of those who are rela-
tively well fed will not also have a long-term impact.  
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    There is only one long-term randomized trial in this 
area, in which premature infants were fed with either a 
standard cows-milk based formula or one enriched with 
additional protein and micro-nutrients. This difference in 
diet, for a median of only four weeks, resulted in ad-
vanced social development and motor coordination at 18 
months144 and in boys but not girls higher intelligence test 
scores at eight years of age.145 At sixteen years of age 
intelligence scores were still greater and imaging studies 
demonstrated that the caudate nucleus was larger in those 
who had consumed the enriched formula.146 This study 
established the principle that even in those who are ap-
parently well fed small changes in diet at a critical stage 
can have long-term consequences. These findings gener-
ate many questions and few answers. It is unclear how 
critical it was that the infants were premature and hence 
that the brain was at an early stage of development. We 
cannot begin to suggest which nutrients, at what doses, 
were responsible for this long-term change in cognitive 
functioning and brain structure. The study does, however, 
establish the principle that the small sub-clinical differ-
ences in diet can have long-term consequences. One can 
speculate that the nature of nutrition, prior to birth, might 
in this way contributes to ‘cognitive reserve’ and hence 
the incidence of dementia late in life. 
    Having considered neural development, a second con-
sideration is the time scale of any subsequent cognitive 
decline. One approach to this question is to use imaging 
techniques to establish the volume of the brain and relate 
this to the volume of the skull measured using X-rays. 
The size of the skull is constant whereas the size of the 
brain declines. Such an approach shows that the shrinkage 
of the brain occurs progressively beginning at about 20 
years of age.147 Studies of cognitive functioning similarly 
find that average measures of episodic memory decline 
with age, scores being the highest in the youngest group 
tested; those from 35 to 40 years.57 This evidence of age-
related changes in the brain’s structure and functioning 
early in life, contrasts with the time scale over which de-
mentia begins to occur: only 1% of the population will be 
diagnosed with dementia at 65 years. It seems that the 
aging process occurs over a long period, such that brain 
shrinkage begins up to sixty years before dementia is di-
agnosed. It is reasonable to suggest that any influence of 
diet may prove to be slow and progressive, such that diet 
is going to be influential over a much extended period. 
The question arises as to whether, to date, intervention 
studies have lasted for a period long enough to protect 
against the aging process. For example, has the failure of 
intervention studies to find a beneficial response to anti-
oxidant micro-nutrients been simply a reflection of stud-




If this analysis of the time scale of the influence of nutri-
tion is accurate there are considerable methodological 
implications.148 The picture is of diet influencing brain 
development; and then in the adult, having a slow impact 
over many decades. The desire is always for evidence of 
causality that comes from randomized controlled double-
blind trials. It is, however, difficult to see how dietary 
intervention trials can last a life time, beginning with the 
manipulation of the diet of the pregnant woman. Few 
would question the desirability of intervention studies, 
but to what extent are they possible in the present context?  
Individuals cannot be blindly allocated to a dietary pat-
tern that they will follow for a life-time.    
    Alternative approaches need to be taken. In many in-
stances there may be little alternative to epidemiology, 
that has been said to allow causality to be assumed when 
the data satisfy a demanding range of criteria.149 This 
does not necessarily cause a problem as questions such as 
the influence of smoking on health have not been subject 
to intervention studies, although its adverse influence has 
been demonstrated using an epidemiological approach.   
    There is, however, a natural desire to use randomized 
trials given their obvious advantages, although this inevi-
tably will have to be over a shorter time period: if so it is 
unlikely that cognitive decline, as such, will be a suitable 
dependant variable. In most instances changes in cogni-
tive functioning simply do not occur to a sufficient extent 
over a short time period. An alternative may be to find 
suitable biomarkers that have been found to have a well 
established relationship with cognitive decline. The anal-
ogy is with heart disease where a demonstration of a de-
cline in blood cholesterol levels is viewed as beneficial. 
To date firmly established biomarkers in the area of cog-
nitive decline do not exist, although some candidates are 
discussed above. Alternatively rather than looking for 
changes in cognition functioning we might use imaging 
techniques to monitor changes in brain structure, perhaps 
considering brain shrinkage in areas known to be associ-
ated with dementia or alternatively measures of cerebral 
blood flow. 
 
Nutrition in context 
Any attempt to use nutritional means to either stimulate 
the development of cognitive functioning, or slow its de-
cline, needs to be kept in context. Although diet is viewed 
in many sections of the population as the cause of prob-
lems and the means of solving them, it should be remem-
bered that although diet influences bodily functioning it is 
by no means the only important factor. Diet needs to be 
kept in context. Logically all that diet can do is to modify 
biological functioning: it can increase potential but the 
exploitation of that potential, with a resulting enhance-
ment of cognitive functioning, also requires a stimulating 
and supportive psychological and social environment. An 
interaction between nutrition and a stimulating environ-
ment can have long-term consequences.  
    Although diet influences the incidence of dementia, it 
occurs less frequently in those who take regular exercise, 
have mentally stimulating interests, have benefited from 
extended education, do not smoke, are not over-weight, 
have a wide circle of friends and social contacts.150,151 A 
good diet may potentially reduce the risk of dementia, but 
in the absence of a range of other factors diet may have 
little influence.   
    Similarly there is evidence that a child’s development 
is modified by factors other than diet. The developmental 
implications of providing psychosocial stimulation (struc-
tured play) for malnourished children has been studied.152  
Six months after discharge from hospital those who had 
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stimulating play were developmentally ahead of a similar 
malnourished group although both had received remedial 
nutrition. A combination of both an improved diet and 
stimulation resulted in development similar to a group of 
children without a history of malnutrition.  
    A study in Jamaica followed up children who had been 
stunted in early childhood. Beginning at 9 to 24 months, 
for two years they received dietary supplements, stimula-
tion (demonstrations of the use of toys), or both.153  Per-
ceptual-motor ability benefited from stimulation although 
supplementation only helped the children of mothers who 
had better verbal ability. After two years supplementation 
and stimulation had an additive effect, although this was 
no longer apparent after four years. The sample was fol-
lowed up at 11 to 12 years of age although no benefit of 
supplementation was found in terms of growth or cogni-
tive functioning.154 In contrast, children who had received 
stimulation had significantly higher intelligence scores. 
At 17 to 18 years of age the group was again examined 
and there was no significant effect of nutritional supple-
mentation, although stunted non-stimulated participants 
had significantly poorer scores than the non-stunted chil-
dren.155 Again a history of stimulation was associated 
with higher intelligence scores. 
    It seems as if the effects of dietary supplementation, if 
provided by itself, might be short lived. Clearly the inten-
tion of improving diet is to provide long-term benefits. 
When implementing such a programme, or alternatively 
developing a food item with supposed beneficial conse-
quences, the extent to which it is reasonable to expect diet 
by itself to have an impact should be considered. It is 
reasonable to suggest that dietary interventions should 
only be one part of a coordinated approach. After critical 
early stages in brain development have passed, a change 
in diet will have a short-term influence on biological po-
tential. Without the opportunity to exploit that potential 
offered by a stimulating environment, the dietary inter-
vention cannot have long-term impact. A similar conclu-
sion is associated with epidemiological studies and short-
term controlled trials. There is a need to monitor and take 
into account many aspects of the environment, as diet is 
likely to be influential under some circumstances and not 
others. The placing of diet into a broader picture will 




The Symposium on Nutrition and Cognition successfully 
reviewed the role of nutrition on the cognitive develop-
ment at early life stage and on cognitive decline in later 
life. It is recognized that the assessment of cognitive 
functioning is central to the study of such topics. Al-
though often hoped for, there is unfortunately no standard 
cognitive test batteries that are suitable for general use. 
Rather, assessment tools need to be tailored to the target 
groups and research needs. Advances in technology have 
looked to bring forth biomarkers capable of monitoring 
physiological changes in the brain. These tools, coupled 
with behavioural cognitive assessment may be used to 
measure the effect of some nutrients on specific cognitive 
domains. Collaboration and the sharing of expertise be-
tween nutritionists, psychologists and cognitive scientists 
are very important for research in this area.  
    Following the recommendation from the symposium, 
ILSI SEA Region will continue to address the assessment 
of cognitive functioning as a follow-up action. Starting 
with the assessment of cognitive development for infant 
and young children, ILSI SEA Region aims to provide a 
better understanding of brain and cognitive development 
in early life, and how to assess the role of nutrients in this 
critical period of development. The report and follow-up 
activity will hopefully serve as valuable resources for 
researchers and health professionals to advance both re-
search and the use/dissemination of the findings in this 
area, particularly in the Southeast Asia region. 
 
ACKNOWLEDGEMENT 
The authors thank the speakers of the Symposium on Nutrition 
and Cognition for providing the materials for report preparation: 
J Steven Reznick; Saskia Osendarp; Peter Willatts; Namsoo 
Chang; Lindawati Wibowo; Srinivasan Krishnamachari; Mi-
chael Fenech; Andrew Sinclair; Suzana Shahar; Paramjeet 
Singh; Andrew Scholey; Rachel Galli; Rema Vazhappilly; 
Jeroen Schmitt; Kathryn Ellis; Richard Head; Toshio Shimizu; 
Rob Winwood and  Josephine Wills. (http://www.ilsi.org/SEA_ 
Region/Pages/NutCogSpeakers.aspx) 
 
AUTHOR DISCLOSURES  




1. Georgieff MK. Nutrition and the developing brain: nutrient 
priorities and measurement. Am J Clin Nutr. 2007;85: 
614S-20S. 
2. Bryce J, Coitinho D, Darnton-Hill I, Pelletier D, Pinstrup-
Andersen P; Maternal and hild Undernutrition Study Group. 
Maternal and child undernutrition: effective action at 
national level. Lancet. 2008;371:510-26. 
3. Micronutrient Initiative. Investing in the future: A united 
call to action for vitamin and mineral deficiencies. 2009 
[cited 2011/4/27]; Available from: http://www. 
unitedcalltoaction.org/documents/Investing_in_the_future.
pdf 
4. Bhutta ZA, Ahmed T, Black RE, Cousens S, Dewey K, 
Giugliani E et al. What works? Interventions for maternal 
and child undernutrition and survival. Lancet. 2008;371: 
417-40. 
5. Black RE, Allen LH, Bhutta ZA, Caulfield LE, de Onis M, 
Ezzati M, Mathers C, Rivera J; Maternal and Child 
Undernutrition Study Group. Maternal and child 
undernutrition: global and regional exposures and health 
consequences. Lancet. 2008;371:243-60. 
6. de Benoist B, McLean E, Egli I, Cogswell M (Eds). 
Worldwide prevalence of anaemia 1993-2005: WHO global 
database on anaemia. Geneva: World Health Organization. 
2008. [cited 2011/4/27]; Available from: http:// 
whqlibdoc.who.int/publications/2008/9789241596657_eng.
pdf 
7. Thompson RA, Nelson CA. Developmental science and the 
media: Early brain development. Am Psychol. 2001;56:5-
15. 
8. Piaget J. The psychology of the child. New York: Basic 
Books; 1972. 
9. Muhlhausler BS, Adam CL, Findlay PA, Duffield JA, 
McMillen IC. Increased maternal nutrition alters 
development of the appetite-regulating network in the brain. 
 Symposium on nutrition and cognition   119 
 
FASEB J. 2006;20:1257-9. 
10. Lozoff B, Georgieff MK. Iron deficiency and brain 
development. Semin Pediatr Neurol. 2006;13:158-65. 
11. Sachdev H, Gera T, Nestel P. Effect of iron 
supplementation on mental and motor development in 
children: systematic review of randomised controlled trials. 
Public Health Nutr. 2005;8:117-32.  
12. Grantham-McGregor S, Ani C. A review of studies on the 
effect of iron deficiency on cognitive development in 
children. J Nutr. 2001;131:649S-66S. 
13. Beard J. Iron deficiency alters brain development and 
functioning. J Nutr. 2003;133:1468S-72S. 
14. Beard JL. Why iron deficiency is important in infant 
development. J Nutr. 2008;138:2534-6. 
15. Lavado-Autric R, Ausó E, García-Velasco JV, Arufe Mdel 
C, Escobar del Rey F, Berbel P, Morreale de Escobar G. 
Early maternal hypothyroxinemia alters histogenesis and 
cerebral cortex cytoarchitecture of the progeny. J Clin 
Invest. 2003;111:1073-82. 
16. Pop VJ, Brouwers EP, Vader HL, Vulsma T, van Baar AL, 
de Vijlder JJ. Maternal hypothyroxinaemia during early 
pregnancy and subsequent child development: a 3-year 
follow-up study. Clin Endocrinol. 2003;59:282-8. 
17. Qian M, Wang D, Watkins WE, Gebski V, Yan YQ, Li M, 
Chen ZP. The effects of iodine on intelligence in children: a 
meta-analysis of studies conducted in China. Asia Pac J 
Clin Nutr. 2005;14:32-42. 
18. Zimmermann MB, Connolly K, Bozo M, Bridson J, Rohner 
F, Grimci L. Iodine supplementation improves cognition in 
iodine-deficient schoolchildren in Albania: a randomized, 
controlled, double-blind study. Am J Clin Nutr. 2006;83: 
108-14. 
19. Frederickson CJ, Suh SW, Silva D, Frederickson CJ, 
Thompson RB. Importance of zinc in the central nervous 
system: the zinc-containing neuron. J Nutr. 2000;130: 
1471S-83S. 
20. Choi SW, Mason JB. Folate and carcinogenesis: an 
integrated scheme. J Nutr. 2000;130:129-32. 
21. Schlotz W, Jones A, Phillips DI, Gale CR, Robinson SM, 
Godfrey KM. Lower maternal folate status in early 
pregnancy is associated with childhood hyperactivity and 
peer problems in offspring. J Child Psychol Psychiatry. 
2010;51:594-602. 
22. Tamura T, Goldenberg RL, Chapman VR, Johnston KE, 
Ramey SL, Nelson KG. Folate status of mothers during 
pregnancy and mental and psychomotor development of 
their children at five years of age. Pediatrics. 2005;116: 
703-8. 
23. Casella EB, Valente M, de Navarro JM, Kok F. Vitamin 
B12 deficiency in infancy as a cause of developmental 
regression. Brain Dev. 2005;27:592-4. 
24. Eilander A, Gera T, Sachdev HS, Transler C, van der Knaap 
HC, Kok FJ, Osendarp SJ. Multiple micronutrient 
supplementation for improving cognitive performance in 
children: systematic review of randomized controlled trials. 
Am J Clin Nutr. 2010;91:115-30. 
25. Copenhagen Consensus Center. Copenhagen Consensus 




26. Martinez M. Tissue levels of polyunsaturated fatty acids 
during early human development. J Pediatr. 1992;120: 
S129-138. 
27. Connor WE, Lowensohn R, Hatcher L. Increased 
docosahexaenoic acid levels in human newborn infants by 
administration of sardines and fish oil during pregnancy. 
Lipids. 1996;31: S183-7. 
28. Helland IB, Saugstad OD, Smith L, Saarem K, Solvoll K, 
Ganes T, Drevon CA. Similar effects on infants of n-3 and 
n-6 fatty acids supplementation to pregnant and lactating 
women. Pediatrics. 2001;108:e82-e92. 
29. Yuhas R, Pramuk K, Lien EL. Human milk fatty acid 
composition from nine countries varies most in DHA. 
Lipids. 2006;41:851-8. 
30. Willatts P, Forsyth JS. The role of long-chain 
polyunsaturated fatty acids in infant cognitive development. 
Prostaglandins Leukot Essent Fatty Acids. 2000;63:95-100. 
31. Eilander A, Hundscheid DC, Osendarp SJ, Transler C, Zock 
PL. Effects of n-3 long chain polyunsaturated fatty acid 
supplementation on visual and cognitive development 
throughout childhood: A review of human studies. 
Prostaglandins Leukot Essent Fatty Acids. 2007;76:189-
203. 
32. Colombo J, Kannass N, Shaddy DJ, Kundurthi S, Maikranz, 
JM, Anderson CJ, Blaga OM, Carlson SE. Maternal DHA 
and the development of attention in infancy and 
toddlerhood. Child Dev. 2004;75:1254-67. 
33. Clausen U, Damli A, con Schenck U, Koletzko B. Influence 
of long-chain polyunsaturated fatty acids (LCPUFA) on 
early visual acuity and mental development of term infants. 
Abstracts American Oil Chemist’s Society Conference  
PUFA in Infant Nutrition: Consensus and Controversies, 
Champaign: 1996; 12. 
34. Willatts P. Development of means-end behavior in young 
infants: Pulling a support to retrieve a distant object. Dev 
Psychol. 1999;35:651-67. 
35. Willatts P, Forsyth JS, Dimodugno MK, Varma S, Colvin M. 
Effect of long-chain polyunsaturated fatty acids in infant 
formula on problem solving at age 10 months of age. 
Lancet. 1998;352:668-91. 
36. Judge MP, Harel O, Lammi-Keefe CJ. Maternal 
consumption of a docosahexaenoic acid-containing 
functional food during pregnancy: benefit for infant 
performance on problem-solving but not on recognition 
memory tasks at age 9 mo. Am J Clin Nutr. 2007; 85:1527-
77. 
37. Jensen CL, Voigt RG, Prager TC, Zou YL, Fraley JK, 
Rozelle JC, Turcich MR, Llorente AM, Anderson RE, 
Heird WC. Effects of maternal docosahexaenoic acid intake 
on visual function and neurodevelopment in breastfed term 
infants. Am J Clin Nutr. 2005;82:125-32. 
38. Helland IB, Smith L, Saarem K, Saugstad OD, Drevon, CA. 
Maternal supplementation with very-long-chain n-3 fatty 
acids during pregnancy and lactation augments children’s 
IQ at 4 years of age. Pediatrics. 2003;111:e39-e44. 
39. Richardson AJ, Montgomery P. The Oxford-Durham study: 
a randomized, controlled trial of dietary supplementation 
with fatty acids in children with developmental 
coordination disorder. Pediatrics. 2005; 115:1360-6. 
40. Ryan AS, Nelson EB. Assessing the effect of 
docosahexaenoic acid on cognitive functions in healthy, 
preschool children: a randomized, placebo-controlled, 
double-blind study. Clin Pediatr (Phila). 2008;47:355-62.  
41. Isaacs E, Oates J; ILSI Europe a.i.s.b.l. Nutrition and 
cognition: assessing cognitive abilities in children and 
young people. Eur J Nutr. 2008;47 (Suppl 3):4-24. 
42. Fenson L, Dale PS, Reznick JS, Thal D, Bates E, Hartung 
JP, Pethick S, Reilly JS. The MacArthur Communicative 
Development Inventories: User’s Guide and Technical 
Manual. Baltimore : Paul H. Brokes Publishing Co; 1993. 
43. Van de Vijver FJR, Poortinga YH. Conceptual and 
methodological issues in adapting tests. In: Hambleton R K, 
Merenda PF, Spielberger CD (Eds.). Adapting educational 
120 D Benton, P Winichagoon, TP Ng, ES Tee and M Isabelle 
 
and psychological tests for cross-cultural assessment. 
Mahwah, NJ: Lawrence Erlbaum Associates; 2003. p.39-63. 
44. Van de Vijver FJR. Test adaptation / translation methods. In: 
Fernadez-Baleesteros R, editor. Encyclopedia of 
psychological assessment, Thousand Oaks,CA: Sage 
Publications; 2003. pp.960-63. 
45. Kaufman AS, Kaufman NL. Kaufman assessment battery 
for children second edition. Circle Pines, MN: American 
Guidance Service; 2004. 
46. McGrew KS. The Cattell-Horn-Carroll theory of cognitive 
abilities: Past, present, and future. In: Flanagan DP, 
Harrison PL, editors. Contemporary intellectual assessment: 
Theories, tests, and issues. New York: The Guilford Press; 
2005. pp.136-81. 
47. Malda M, van de Vijver FJ, Srinivasan K, Transler C, 
Sukumar P, Rao K. Adapting a cognitive test for a different 
culture: An illustration of qualitative procedures. Psychol 
Sci Quart. 2008;50:451-68. 
48. Hambleton RK. Issues, designs, and technical guidelines 
for adapting tests into multiple languages and cultures. In: 
Hambleton RK, Merenda PF, Spielberger CD, editors. 
Adapting educational and psychological tests for cross-
cultural assessment. Mahwah, NJ: Lawrence Erlbaum 
Associates; 2005. pp.3-38. 
49. Malda M, van de Vijver FJ, Srinivasan K, Transler C, 
Sukumar P. Traveling with cognitive tests: testing the 
validity of a KABC-II adaptation in India. Assessment. 
2010;17: 107-15. 
50. The Nemo Study Group. Effect of a 12-mo micronutrient 
intervention on learning and memory in well-nourished and 
marginally-nourished school-aged children: parallel, 
randomized, placebo-controlled studies in Australia and 
Indonesia. Am J Clin Nutr. 2007;86:1082-93. 
51. Muthayya S, Eilander A, Transler C, Thomas T, van der 
Knaap HC, Srinivasan K, van Klinken BJ, Osendarp SJ, 
Kurpad AV. Effect of fortification with multiple 
micronutrients and n-3 fatty acids on growth and cognitive 
performance in Indian schoolchildren: the CHAMPION 
(Children's Health and Mental Performance Influenced by 
Optimal Nutrition) Study. Am J Clin Nutr. 2009;89:1766-
75. 
52. Veena SR, Krishnaveni GV, Srinivasan K, Wills AK, 
Muthayya S, Kurpad AV, Yajnik CS, Fall CH. Higher 
maternal plasma folate but not vitamin B-12 concentrations 
during pregnancy are associated with better cognitive 
function scores in 9- to 10- year-old children in South India. 
J Nutr. 2010;140:1014-22. 
53. Manger MS, McKenzie JE, Winichagoon P, Gray A, 
Chavasit V, Pongcharoen T, Gowachirapant S, Ryan B, 
Wasantwisut E, Gibson RS. A micronutrient-fortified 
seasoning powder reduces morbidity and improves short-
term cognitive function, but has no effect on 
anthropometric measures in primary school children in 
northeast Thailand: a randomized controlled trial. Am J 
Clin Nutr. 2008;87: 1715-22. 
54. Nga TT, Winichagoon P, Dijkhuizen MA, Khan NC, 
Wasantwisut E, Furr H, Wieringa FT. Multi-micronutrient-
fortified biscuits decreased prevalence of anemia and 
improved micronutrient status and effectiveness of 
deworming in rural Vietnamese school children. J Nutr. 
2009;139: 1013-21. 
55. Pongcharoen T, DiGirolamo AM, Ramakrishnan U, 
Winichagoon P, Flores R, Martorell R. Long-term effects of 
iron and zinc supplementation during infancy on cognitive 
function at 9 y of age in northeast Thai children: a follow-
up study. Am J Clin Nutr. 2011;93:636-43.  
56. Benton D, Kallus KW, Schmitt JAJ. How should we 
measure nutrition-induced improvements in memory? Eur J 
Nutr. 2005;44:485-98. 
57. Nilsson LG. Memory function in normal aging. Acta Neurol 
Scand. 2003;107:7-3. 
58. Lu T, Pan Y, Kao SY, Li C, Kohane I, Chan J, Yankner BA. 
Gene regulation and DNA damage in the ageing human 
brain. Nature. 2004;429:883-91. 
59. Migliore L, Fontana I, Trippi F, Colognato R, Coppedè F, 
Tognoni G, Nucciarone B, Siciliano G. Oxidative DNA 
damage in peripheral leukocytes of mild cognitive 
impairment and AD patients. Neurobiol Aging. 
2005;26:567-73. 
60. Thomas P, O' Callaghan NJ, Fenech M. Telomere length in 
white blood cells, buccal cells and brain tissue and its 
variation with ageing and Alzheimer's disease. Mech 
Ageing Dev. 2008;129:183-90. 
61. Gillette Guyonnet S, Abellan Van Kan G, Andrieu S, 
Barberger Gateau P, Berr C, Bonnefoy M et al. IANA task 
force on nutrition and cognitive decline with aging. J Nutr 
Health Aging. 2007;11:132-52. 
62. Fenech M, Baghurst P, Luderer W, Turner J, Record S, 
Ceppi M, Bonassi S. Low intake of calcium, folate, 
nicotinic acid, vitamin E, retinol, beta-carotene and high 
intake of pantothenic acid, biotin and riboflavin are 
significantly associated with increased genome instability--
results from a dietary intake and micronucleus index survey 
in South Australia. Carcinogenesis. 2005;26:991-9. 
63. Munro HN. Nutrition of the elderly: Introduction. In: 
Munro HN, Schlief G, Nestle A, ed. Nutrition of the Elderly. 
Nutrition Workshop Series. Vevey: Nestec/New York: 
Raven Press. 1992;29:1-5. 
64. Mattson MP, Shea TB. Folate and homocysteine 
metabolism in neural plasticity and neurodegenerative 
disorders. Trends Neurosci. 2003;26:137-46. 
65. Bull CF, O'Callaghan NJ, Mayrhofer G, Fenech MF. 
Telomere length in lymphocytes of older South Australian 
men may be inversely associated with plasma 
homocysteine. Rejuvenation Res. 2009;12:341-9. 
66. Feng L, Ng TP, Chuah L, Niti M, Kua EH. Homocysteine, 
folate, and vitamin B-12 and cognitive performance in 
older Chinese adults: findings from the Singapore 
Longitudinal Ageing Study. Am J Clin Nutr. 2006;84:1506-
12. 
67. Lee LK, Shahar S, Rajab N. Serum folate concentration, 
cognitive impairment, and DNA damage among elderly 
individuals in Malaysia. Nutr Res. 2009;29:327-34. 
68. Wang B, Jin F, Kan R, Ji S, Zhang C, Lu Z, Zheng C, Yang 
Z, Wang L. Association of MTHFR gene polymorphism 
C677T with susceptibility ot late-onset Alzheimer’s disease. 
J Mol Neurosci. 2005;27:23-7. 
69. Feng L, Niti M, Yap KB, Kua EH, Ng TP. Vitamin B-12, 
Apolipoprotein E genotype and cognitive performance: 
Evidence of gene-nutrition interaction. Am J Clin Nutr. 
2009;89:1263-8. 
70. Diau GY, Hsieh AT, Sarkadi-Nagy EA, Wijendran V, 
Nathanielsz PW, Brenna JT. The influence of long chain 
polyunsaturate supplementation on docosahexaenoic acid 
and arachidonic acid in baboon neonate central nervous 
system. BMC Med. 2005;3:11. 
71. Feller SE, Gawrisch K, MacKerell AD Jr. Polyunsaturated 
fatty acids in lipid bilayers: intrinsic and environmental 
contributions to their unique physical properties. J Am 
Chem Soc. 2002;124:318-26. 
72. Kitajka K, Puskás LG, Zvara A, Hackler L Jr, Barceló-
Coblijn G, Yeo YK, Farkas T. The role of n-3 
polyunsaturated fatty acids in brain: modulation of rat brain 
gene expression by dietary n-3 fatty acids. Proc Natl Acad 
 Symposium on nutrition and cognition   121 
 
Sci USA. 2002;99:2619-24. 
73. Bazan NG. Neuroprotectin D1-mediated anti-inflammatory 
and survival signalling in stroke, retinal degenerations, and 
Alzheimer's disease. J Lipid Res. 2009;50 Suppl:S400-5. 
74. Rao JS, Ertley RN, Lee HJ, DeMar JC Jr, Arnold JT, 
Rapoport SI, Bazinet RP. n-3 polyunsaturated fatty acid 
deprivation in rats decreases frontal cortex BDNF via a p38 
MAPK-dependent mechanism. Mol Psychiatry. 2007;12: 
36-46. 
75. Suphioglu C, De Mel D, Kumar L, Sadli N, Freestone D, 
Michalczyk A, Sinclair A, Ackland ML. The omega-3 fatty 
acid, DHA, decreases neuronal cell death in association 
with altered zinc transport. FEBS Lett. 2010;584:612-8. 
76. Chisaki K, Okuda Y, Suzuki S, Miyauchi T, Soma M, 
Ohkoshi N, Sone H, Yamada N, Nakajima T. 
Eicosapentaenoic acid suppresses basal and insulin-
stimulated endothelin-1 production in human endothelial 
cells. Hypertens Res. 2003;26:655-61. 
77. Calon F, Lim GP, Yang F, Morihara T, Teter B, Ubeda O et 
al. Docosahexaenoic acid protects from dendritic pathology 
in an Alzheimer's disease mouse model. Neuron. 2004;43: 
633-45. 
78. Cole GM, Frautschy SA. Docosahexaenoic acid protects 
from amyloid and dendritic pathology in an Alzheimer's 
disease mouse model. Nutr Health. 2006;18:249-59. 
79. Huang TL. Omega-3 fatty acids, cognitive decline, and 
Alzheimer’s disease: A critical review and evaluation of the 
literature. J Alzheimers Dis. 2010;21:673-9. 
80. Lim WS, Gammack JK Van Niekerk JK, Dangour A. 
Omega 3 fatty acid for the prevention of dementia. 
Cochrane Database of Systematic Reviews 2006, Issue 1. 
Art. No.: CD005379. DOI: 
10.1002/14651858.CD005379.pub2.  
81. Yurko-Mauro K, McCarthy D, Rom D, Nelson EB, Ryan 
AS, Blackwell A, Salem N Jr, Stedman M; on behalf of the 
MIDAS Investigators. Beneficial effects of 
docosahexaenoic acid on cognition in age-related cognitive 
decline. Alzheimers Dement. 2010;6:456-64. 
82. Vakhapova V, Cohen T, Richter Y, Herzog Y, Korczyn AD. 
Phosphatidylserine containing omega-3 fatty acids may 
improve memory abilities in non-demented elderly with 
memory complaints: a double-blind placebo-controlled trial. 
Dement Geriatr Cogn Disord. 2010;29:467-74. 
83. Bogen IL, Risa Ø, Haug KH, Sonnewald U, Fonnum F, 
Walaas SI. Distinct changes in neuronal and astrocytic 
amino acid neurotransmitter metabolism in mice with 
reduced numbers of synaptic vesicles. J Neurochem. 2008; 
105:2524-34. 
84. Keller KA, Chu Y, Grider A, Coffield JA. Supplementation 
with L-histidine during dietary zinc repletion improves 
short-term memory in zinc-restricted young adult male rats. 
J Nutr. 2000;130:1633-40. 
85. Cole JT, Mitala CM, Kundu S, Verma A, Elkind JA, Nissim 
I, Cohen AS. Dietary branched chain amino acids 
ameliorate injury-induced cognitive impairment. Proc Natl 
Acad Sci USA. 2010;107:366-71. 
86. Min J, Senut MC, Rajanikant K, Greenberg E, Bandagi R, 
Zemke D et al. Differential neuroprotective effects of 
carnosine, anserine, and N-acetyl carnosine against 
permanent focal ischemia. J Neurosci Res. 2008;86:2984-
91. 
87. Boldyrev AA, Stvolinsky SL, Fedorova TN, Suslina ZA. 
Carnosine as a natural antioxidant and geroprotector: from 
molecular mechanisms to clinical trials. Rejuvenation Res. 
2010;13:156-8. 
88. Wang AM, Ma C, Xie ZH, Shen F. Use of carnosine as a 
natural anti-senescence drug for human beings. 
Biochemistry. 2000;65:869-71. 
89. Leung LK, Su Y, Chen R, Zhang Z, Huang Y, Chen ZY.  
Theaflavins in black tea and catechins in green tea are 
equally effective antioxidants. J Nutr. 2001;131:2248-51. 
90. Weinreb O, Mandel S, Amit T, Youdim MB. Neurological 
mechanisms of green tea polyphenols in Alzheimer's and 
Parkinson's diseases. J Nutr Biochem. 2004;15:506-16.  
91. Mandel S, Youdim MB. Catechin polyphenols: 
neurodegeneration and neuroprotection in 
neurodegenerative diseases. Free Radic Biol Med. 2004 
Aug 1;37:304-17.  
92. Rezai-Zadeh K, Shytle D, Sun N, Mori T, Hou H, Jeanniton 
D et al. Green tea epigallocatechin-3-gallate (EGCG) mod-
ulates amyloid precursor protein cleavage and reduces cer-
ebral amyloidosis in Alzheimer transgenic mice. J Neurosci. 
2005;25:8807-14. 
93. Okello EJ, Savelev SU, Perry EK. In vitro anti-beta-
secretase and dual anti-cholinesterase activities of Camellia 
sinensis L. (tea) relevant to treatment of dementia. 
Phytother Res. 2004;18:624-7. 
94. Nathan PJ, Lu K, Gray M, Oliver C. The 
neuropharmacology of L-theanine (N-ethyl-L-glutamine): a 
possible neuroprotective and cognitive enhancing agent. J 
Herb Pharmacother. 2006;6:21-30.  
95. Kuriyama S, Hozawa A, Ohmori K, Shimazu T, Matsui T, 
Ebihara S, Awata S,Nagatomi R, Arai H, Tsuji I.  Green tea 
consumption and cognitive function: a cross-sectional 
study from the Tsurugaya Project 1. Am J Clin Nutr. 2006; 
83:355-61. 
96. Feng L, Gwee XY, Kua EH, Ng TP. Cognitive functioning 
associated with tea consumption in non-demented Chinese 
older adults in the Singapore Longitudinal Ageing Study 
Cohort. J Nutr Health Aging. 2010;14:433-8. 
97. Joseph JA, Shukitt-Hale B, Willis LM. Grape juice, berries, 
and walnuts affect brain aging and behaviour. J Nutr. 
2009;139:1813S-7S. 
98. Andres-Lacueva C, Shukitt-Hale B, Galli RL, Jauregui O, 
Lamuela-Raventos RM, Joseph JA. Anthocyanins in aged 
blueberry-fed rats are found centrally and may enhance 
memory. Nutr Neurosci. 2005;8:111-20. 
99. Casadesus G, Shukitt-Hale B, Stellwagen HM, Zhu X, Lee 
HG, Smith MA, Joseph JA. Modulation of hippocampal 
plasticity and cognitive behaviour by short-term blueberry 
supplementation in aged rats. Nutr Neurosci. 2004;7:309-
16. 
100. Krikorian R, Shidler MD, Nash TA, Kalt W, Vinqvist-
Tymchuk MR, Shukitt-Hale B, Joseph JA. Blueberry 
supplementation improves memory in older adults. J Agric 
Food Chem. 2010;58:3996-4000. 
101. Lim GP, Chu T, Yang F, Beech W, Frautschy SA, Cole GM. 
The curry spice curcumin reduces oxidative damage and 
amyloid pathology in an Alzheimer transgenic mouse. J 
Neurosci. 2001;21:8370-7. 
102. Ng TP, Chiam PC, Lee T, Chua HC, Lim L, Kua EH. Curry 
consumption and cognitive function in the elderly. Am J 
Epidemiol. 2006;164:898-906. 
103. Francis ST, Head K, Morris PG, Macdonald IA. The effect 
of flavanol-rich cocoa on the fMRI response to a cognitive 
task in healthy young people. J Cardiovasc Pharmacol. 
2006;47 Suppl 2:S215-20. 
104. Nurk E, Refsum H, Drevon CA, Tell GS, Nygaard HA, 
Engedal K, Smith AD. Intake of flavonoid-rich wine, tea, 
and chocolate by elderly men and women is associated 
with better cognitive test performance. J Nutr. 2009;139: 
120-7. 
105. Crews WD Jr, Harrison DW, Wright JW. A double-blind, 
placebo-controlled, randomized trial of the effects of dark 
122 D Benton, P Winichagoon, TP Ng, ES Tee and M Isabelle 
 
chocolate and cocoa on variables associated with 
neuropsychological functioning and cardiovascular health: 
clinical findings from a sample of healthy, cognitively 
intact older adults. Am J Clin Nutr. 2008;87:872-80. 
106. Kennedy DO, Scholey AB, Drewery L, Marsh VR, Moore 
B, Ashton H. Electroencephalograph effects of single doses 
of Ginkgo biloba and Panax ginseng in healthy young 
volunteers. Pharmacol Biochem Behav. 2003;75:701-9. 
107. Geng J, Dong J, Ni H, Lee MS, Wu T, Jiang K, Wang G,        
Zhou AL, Malouf R. Ginseng for cognition. Cochrane 
Database of Systematic Reviews 2010, Issue 12. Art. No.: 
CD007769. DOI: 10.1002/14651858.CD007769.pub2.  
108. 108 Reay JL, Kennedy DO, Scholey AB. Single doses of 
Panax ginseng (G115) reduce blood glucose levels and 
improve cognitive performance during sustained mental 
activity. J Psychopharmacol. 2005;19:357-65. 
109. Scholey AB, Tildesley NT, Ballard CG, Wesnes KA, Tasker 
A, Perry EK, Kennedy DO. An extract of Salvia (sage) 
with anticholinesterase properties improves memory and 
attention in healthy older volunteers. Psychopharmacology. 
2008;198:127-39. 
110. Akhondzadeh S, Noroozian M, Mohammadi M, Ohadinia S, 
Jamshidi AH, Khani M. Salvia officinalis extract in the 
treatment of patients with mild to moderate Alzheimer's 
disease: a double blind, randomized and placebo-controlled 
trial. J Clin Pharm Ther. 2003;28:53-9. 
111. Schmitt JAJ, Benton D, Kallus KW. General 
methodological considerations for the assessment of 
nutritional influences on human cognitive functions. Eur J 
Nutr. 2005;44: 459-64. 
112. Craig-Schapiro R, Fagan AM, Holtzman DM. Biomarkers 
of Alzheimer's disease. Neurobiol Dis. 2009;35:128-40. 
113. Katzman R, Terry R, DeTeresa R, Brown T, Davies P, Fuld 
P, Renbing X, Peck A. Clinical, pathological, and 
neurochemical changes in dementia: a subgroup with 
preserved mental status and numerous neocortical plaques. 
Ann Neurol. 1988;23:138-44. 
114. Rowe CC, Ellis KA, Rimajova M, Bourgeat P, Pike KE, 
Jones G et al. Amyloid imaging results from the Australian 
Imaging, Biomarkers and Lifestyle (AIBL) study of aging. 
Neurobiol Aging. 2010;31:1275-83. 
115. Ng TP, Niti M, Chiam PC, Kua EH. Ethnic differences in 
cognitive performance on Mini-Mental State Examination 
in Asians. Am J Geriatr Psychiatry. 2007;15:130-9. 
116. European Food Safety Authority. General function health 
claims under Article 13. 2010 [cited 2010/11/12]; Available 
from:  
http://www.efsa.europa.eu/en/ndaclaims/ndaclaims13.htm 
117. European Food Safety Authority. Claims on disease risk 
reduction and child development or health under Article 14. 
2008 [cited 2010/11/12]; Available from: http://www. 
efsa.europa.eu/en/ndaclaims/ndaclaims14.htm 
118. Food Standards Australia New Zealand. Nutrition and 
health claims. 2011 [cited 2011/07/07]; Available from: 
http://www.foodstandards.gov.au/consumerinformation/nut
ritionhealthandrelatedclaims/ 
119. Food Standards Australia New Zealand. Standard 1.1A.2 




120. World Health Organization. Active ageing: A policy 
framework. 2002 [cited 2010/11/12]; Available from: 
http://whqlibdoc.who.int/hq/2002/who_nmh_nph_02.8.pdf 
121. May BH, Lit M, Xue CC, Yang AW, Zhang AL, Owens MD 
et al. Herbal medicine for dementia: a systematic review. 
Phytother Res. 2009;23:447-59. 
122. Shaw LM, Korecka M, Clark CM, Lee VM, Trojanowski 
JQ. Biomarkers of neurodegeneration for diagnosis and 
monitoring therapeutics. Nat Rev Drug Discov. 2007;6: 
295-303. 
123. Thorn DC, Meehan S, Sunde M, Rekas A, Gras SL, 
MacPhee CE, Dobson CM, Wilson MR, Carver JA. 
Amyloid fibril formation by bovine milk kappa-casein and 
its inhibition by the molecular chaperones alphaS- and 
beta-casein. Biochemistry. 2005;44:17027-36. 
124. Yang SG, Wang WY, Ling TJ, Feng Y, Du XT, Zhang X et 
al. ,Alpha-tocopherol quinone inhibits beta-amyloid 
aggregation and cytotoxicity, disaggregates preformed 
fibrils and decreases the production of reactive oxygen 
species, NO and inflammatory cytokines. Neurochem Int. 
2010;57:914-22. 
125. ILSI Southeast Asia Region. Meeting Summary: Seminar 
and workshop on nutrition labeling, claims and communi-
cation strategies for the consumer, September 2010,  Kuala 




126. Innova Database. Brain-platform global new products. 
2010 [cited 2010/10/18] Available from: 
http://www.innovadatabase.com/ 
127. Brenna JT, Diau GY. The influence of dietary 
docosahexaenoic acid and arachidonic acid on central 
nervous system polyunsaturated fatty acid composition. 
Prostaglandins Leukot Essent Fatty Acids. 2007;77:247-50. 
128. Joint FAO/WHO Expert Consultation on Fats and Fatty 
Acids in Human Nutrition Interim Summary of 
Conclusions and Dietary Recommendations on Total Fat & 
Fatty Acids. 2008. [cited 2010/11/12]; Available from: 
http://www.who.int/entity/nutrition/topics/FFA_summary_r
ec_conclusion.pdf 
129. Lauritzen L, Hansen HS, Jørgensen MH, Michaelsen KF. 
The essentiality of long chain n-3 fatty acids in relation to 
development and function of the brain and retina. Prog 
Lipid Res. 2001;40:1-94. 
130. Koletzko B, Cetin I, Brenna JT; Perinatal Lipid Intake 
Working Group; Child Health Foundation; Diabetic 
Pregnancy Study Group; European Association of Perinatal 
Medicine; European Association of Perinatal Medicine; 
European Society for Clinical Nutrition and Metabolism; 
European Society for Paediatric Gastroenterology, 
Hepatology and Nutrition, Committee on Nutrition; 
International Federation of Placenta Associations; 
International Society for the Study of Fatty Acids and 
Lipids. Dietary fat intakes for pregnant and lactating 
women. Br J Nutr. 2007;98:873-7. 
131. Lien EL. Toxicology and safety of DHA. Prostaglandins 
Leukot Essent Fatty Acids. 2009;81:125-32. 
132. European Food Safety Authority. Scientific opinion on the 
substantiation of health claims related to docosahexaenoic 
acid (DHA). 2010. [cited 2010/11/12]; Available from: 
http://www.efsa.europa.eu/en/scdocs/doc/1734.pdf 
133. Oleary M, Donnell RM, Johnson H. Folic acid and 
prevention of neural tube defects in 2000 improved 
awareness-low peri-conceptional uptake. Ir Med J. 
2001;94:180-1. 
134. Sen S, Manzoor A, Deviasumathy M, Newton C. Maternal 
knowledge, attitude and practice regarding folic acid intake 
during the periconceptional period. Public Health Nutr. 
2001;4:909-12. 
135. International Food Information Council. 2009 functional 
foods/ foods for health consumer trending survey. 2009. 
[cited 2010/11/12]; Available from: http://www. 




136. International Food Information Council. 2010 food & 
health survey: consumer attitudes toward food safety, 




137. Asian Food Information Centre. Survey of consumer 
responses to front-of-pack nutrition and health information 
in China and Malaysia. 2006. [cited 2010/11/12]; Available 
from: http://afic.org/aficengine/_filesmgr/File/ 2006%20 
Survey%20of%20Consume%20Response%20to%20Front-
of-Pack.pdf 
138. Folstein MF, Folstein SE, McHugh PR. Mini-mental state: 
a practical method for grading the cognitive state of pa-
tients for the clinician. J Psychiatr Res. 1975;12:189-98. 
139. Wind AW, Schellevis FG, Van Staveren G, Scholten RP, 
Jonker C, Van Eijk JTM. Limitations of the mini-mental 
state examination for diagnosing dementia in general 
practice. Int J Geriatr Psychiatr. 1997;12:101-8. 
140. Dangour AD, Sibson VL, Fletcher AE. Micronutrient 
supplementation in later life: limited evidence  for benefit. 
J Gerontol A Biol Sci Med Sci. 2004;59:659-73. 
141. Richards M, Sacker A. Lifetime antecedents of cognitive 
reserve. J Clin Exp Neuropsychol. 2003;25:614-24. 
142. Whalley LJ, Starr JM, Athawes R. Hunter D, Pattie A, 
Deary IJ. Childhood mental ability and dementia. 
Neurology. 2000;55:1455-9. 
143. Benton D. The influence of dietary status on the cognitive 
performance of children. Mol Nutr Food Res. 2010;54: 
457-70. 
144. Lucas A, Morley R, Cole TJ, Gore SM, Lucas PJ, Crowle P, 
Pearse R, Boon AJ, Powell R. Early diet in preterm babies 
and developmental status at 18 months. Lancet. 1990;335: 
1477-81. 
145. Lucas A, Morley R, Cole TJ. Randomised trial of early diet  






























146. Isaacs EB, Gadian DG, Sabatini S, Chong WK, Quinn BT, 
Fischl BR, Lucas A. The effect of early human diet on 
caudate volumes and IQ. Pediat Res. 2008;63:308-14. 
147. Hommer DW, Momenan R, Kaiser E, Rawlings R. 
Evidence for a gender-related effect of alcoholism on brain 
volumes. Am J Psychiat. 2001;158:198-204. 
148. Benton D. Neuro-development and neuro-degeneration – 
are there critical stages for nutritional intervention? Nutr 
Rev. 2010;68:S6-S10. 
149. Bradford-Hill A. The environment and disease: association 
or causation. Proc R Soc Med. 1965;58:295-330. 
150. Savica R, Petersen RC. Prevention of dementia. Psychiatr 
Clin North Am. 2011;34:127-45. 
151. Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D,  
Jones E. Alzheimer's disease.  Lancet. 2011;377:1019-31. 
152. Grantham-McGregor S, Stewart ME, Schofield WN. Effect 
of long-term psychosocial stimulation on mental 
development of severely malnourished children. Lancet. 
1980;316:785-9. 
153. Grantham-McGregor SM, Walker SP, Chang SM, Powell 
CA. Effects of early childhood supplementation with and 
without stimulation on later development in stunted 
Jamaican children. Am J Clin Nutr. 1997;66:247-53. 
154. Walker SP, Grantham-Mcgregor SM, Powell CA, Chang 
SM. Effects of growth restriction in early childhood on 
growth, IQ, and cognition at age 11 to 12 years and the 
benefits of nutritional supplementation and psychosocial 
stimulation. J Pediatr. 2000;137:36-41. 
155. Walker SP, Chang SM, Powell CA, Grantham-McGregor 
SM. Effects of early childhood psychosocial stimulation 
and nutritional supplementation on cognition and education 
in growth-stunted Jamaican children: prospective cohort 
study. Lancet. 2005;19;366:1804-7. 





Symposium on nutrition and cognition: towards research 
and application for different life stages 
 
David Benton DSc1, Pattanee Winichagoon PhD2, Tze Pin Ng PhD3, E Siong Tee PhD4, 
Mia Isabelle BSc5  
 
1 Department of Psychology, University of Swansea, Swansea, Wales, UK  
2 Institute of Nutrition, Mahidol University, Salaya, Thailand  
3 Gerontological Research Programme, Faculty of Medicine, National University of Singapore, Singapore 
4 TES Nutrihealth Strategic Consultancy, Selangor, Malaysia 




於 2010 年 10 月在馬來西亞舉辦「營養與認知研討會：關於不同生命期的研究
與應用」。回顧飲食與營養對兒童認知發展及生命後期認知衰退的影響。這類
主題的研究，其關鍵點在認知功能的評估。認知功能主要包含六個領域：執行
功能、記憶、專注力、理解力、知動能力及語言能力，每個領域還可進一步細
分。由於人類功能的自然本質，任何認知測驗皆反映數項功能領域的綜合表
現；理想的作法，應該用一系列的測試來呈現認知表現的任何差異。在介入性
研究中，經常未能顯現飲食改變的有利影響；一個可能原因是研究無法確認飲
食效益的時間範圍和關鍵年齡。飲食的影響是緩慢漸進的，使得短期研究很難
看到有所改善。此外，因為許多因子會影響人類行為，飲食介入應只是整體對
策的一部分；飲食的效應依個人生活的社會與心理情況而有所不同。將飲食放
在較廣的社會與心理層面上，會大大提昇產生重要發現的機會。本篇報告就研
討會中的簡報與討論做重點描述與回顧。 
 
關鍵字：老化、腦部發展、認知、認知衰退、營養 
 
